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“As we know, there are known knowns; there are things we know we know.  
We also know there are known unknowns; that is to say we know there are some things we 
do not know. But there are also unknown unknowns—the ones we don’t know we don’t 
know.” 
 




Scientific evidence based on health economic evaluations is needed to enable decisions-makers to 
make informed decisions on resource allocations within health care systems. Usually the economic 
evaluations take place within health technology assessment (HTA) framework. The use of health 
economic evaluations has increased during the last two decades and will hopefully contribute 
towards making the best possible use of limited health care resources. 
 
Prostate cancer (PC) is the most frequently diagnosed cancer in men accounting for 29% of all the 
cancers diagnosed in men in Finland. There are almost 50,000 men in Finland currently living with PC. 
The prevalence of PC is expected to rise with aging population and improved diagnostics and 
treatment options. This may also increase the burden from PC on the society and, consequently, 
resource optimization is warranted.  
 
Health-related quality of life (HRQoL) assessments in PC is an evolving field but, based on the 
literature, the use of preference-based single index measures to generate health state utilities or 
values valid for the estimation of quality adjusted life years (QALY) gained, is scarce. This is 
problematic, as health state utility estimates are an integral component of cost-utility analysis, which 
can be considered the gold standard analytical method in health economics today. 
 
The general aim of this thesis was to study HRQoL and costs in different states of PC. This was done 
from the perspective of generating evidence that can be used for the health economic analysis. 
HRQoL was assessed with one cancer-specific (EORTC QLQ-C30) and two generic (EQ-5D-3L and 15D) 
HRQoL instruments. The EQ-5D-3L also included visual analogue scale (VAS). In addition, costs were 
also collected for these patients as incremental costs compared to age, gender and place of 
residence standardised peers.  
 
A total of 1025 PC patients were invited to study, of whom 630 (61.5%) responded. Patients were 
collected in the Helsinki and Uusimaa Hospital District in a cross-sectional setting. PC data were 
collected as a part of a larger study, where similar data were also collected for colorectal cancer 
(CRC) and breast cancer (BC). PC patients ages ranged from 44 to 93 years and most of them had 
local disease and were married or cohabiting and had higher education. Patients were divided into 
five mutually exclusive groups based on disease state: Primary (local disease, first six months after 
diagnosis), Rehabilitation (local disease, 0.5 – 1.5 years after diagnosis or recurrence), Remission 
(local disease, more than 1.5 years after diagnosis), Metastatic (after detection of metastases) and 
Palliative care (no chemo- or radiotherapy and patients who died due to cancer within six months of 
responding). 
 
All evaluated HRQoL instruments provided valuable insight into patients’ overall HRQoL. The 15D 
scores of the study population ranged from 0.344 to 1.000 (mean 0.863), the EQ-5D: -0.166 to 1.000 
(mean 0.845), and the VAS: 1 to 100 (mean 76.4). 30 patients reported having perfect/full health 
(5%) with the 15D and VAS, whereas 266 (42%) patients had same result with the EQ-5D. HRQoL 
remained on a relatively high level until the disease progressed. Symptoms of fatigue and pain, and 
the background variables of financial difficulties and age, were the most important factors associated 
with poor HRQoL.  
 
Current understanding of patients’ HRQoL in terminal stages of cancer is limited. In this study 311 
palliative cancer patients were invited to participate and out of those 114 patients (37%) responded. 
This palliative cancer patient data set included 30 PC patients, 57 CRC patients and 27 BC patients. 
The mean utility scores varied widely depending on the HRQoL instrument used: the 15D gave the 
highest utility values (mean 0.74), followed by the EQ-5D-3L (0.59) and VAS (55.0). The mean utility 
value among PC patients was 0.67 with the 15D, 0.59 with the EQ-5D-3L, and 48.7 with the VAS. With 
the EQ-5D-3L, 13% of the patients received perfect health status (ie., EQ-5D-3L score 1.00). 
 
Direct costs related to different states of PC are significant. In this study, costs are reported as 
incremental costs due to cancer for a six-month period and they include direct medical costs, 
productivity costs and costs of informal care. Resource use and cost data were retrieved from various 
registries and in addition patients answered background questions concerning informal care, work 
capacity and educational status. To analyse incremental cost burden due to cancer, two age, gender 
and place of residence standardised control subjects were extracted from the Social Insurance 
Institution’s electronic records.  
 
Costs differed markedly between the states of disease. Mean direct health care costs for the six-
month periods were: Primary treatment state €2750, Rehabilitation state €1143, remission state 
€760 and Metastatic state €7423. Most of the patients were not working which was expected due to 
their mean age. 102 (16.7%) of the patients were employed and of the 430 retired patients more 
than two-thirds were eligible for the state pension based on their age of 65 years or more. Only 18 
(2.9%) patients received disability pension due to their cancer and 28 patients (4.6%) received 
disability pension due to other reasons. Seventeen patients (2.8%) reported not working or being 
unemployed. The number of days absent from work due to sick leave was relatively low, being on the 
average less than one day during the six-month period, however, the mean number days being 
absent from the work due to early retirement was much higher. Combined total days absent from 
the work were highest in Primary (8.2 days) and Metastatic (12.5 days) groups and lowest in 
Rehabilitation and Remission groups, 5.4 and 4.0 days, respectively.  
 
Productivity costs were therefore highest (€4277) in the metastatic state. Overall, the average share 
of indirect costs was around one third of the total costs. However, when including informal care, 
their combined share of the total costs increased to around half or more. The mean number of 
informal care received from patient’s family or others was modest around one hour or less per week, 
and it was reported only by 34 patients (5.6%). Based on study results productivity losses and costs of 
informal care can play a major role when estimating the total economic burden of PC. Excluding such 
a large share of costs from assessments might have a significant impact on the decision making pro-
cess of health economic evaluations or HTA. 
 
The single-index HRQoL instruments considered here (EQ-5D-3L and 15D) should not be considered 
interchangeable in health economic evaluations, especially in the case where HRQoL values are low 
or differ significantly from those of age-standardised peers. The EQ-5D-3L produces greater 
differences in utilities than the 15D. Some of the earlier studied issues like the marked ceiling effect, 
two-peaked, discontinuous distribution of the EQ-5D scores, as well as the higher HRQoL scores 
obtained by the 15D compared to EQ-5D-3L were also evident from the PC material. Thus, these 
differences need to be taken into consideration when these instruments and their results are used in 




Terveystaloudellisiin arviointeihin perustuvaa tieteellistä näyttöä tarvitaan, jotta päätöksentekijät 
voivat tehdä perusteltuja päätöksiä resurssien kohdentamisesta terveydenhuoltojärjestelmissä. 
Arvioinneissa tiivistetään ja arvioidaan tutkimusnäyttöä hoitojen hyödyistä, haitoista, kustannuksista 
ja kustannusvaikuttavuudesta muihin hoitovaihtoehtoihin verrattuna. Tutkimusnäytön kokoamisessa 
ja arvioinnissa hyödynnetään terveysteknologian arvioinnin lähestymistapoja (HTA). 
Terveystaloudellisten arvioiden käyttö on kasvanut viimeisten kahden vuosikymmenen aikana ja 
nämä ovat osaltaan tukeneet niukkojen terveydenhuollon resurssien mahdollisimman tehokasta 
hyödyntämistä. 
 
Eturauhassyöpä (PC) on yleisimmin todettu syöpä miehillä, mikä vastaa 29 prosenttia kaikista 
miehillä Suomessa diagnosoiduista syöpätaudeista. Suomessa on tällä hetkellä lähes 50 000 
eturauhassyövän kanssa elävää miestä. Taudin esiintyvyyden odotetaan kasvavan väestön 
ikääntyessä ja diagnostiikka- ja hoitovaihtoehtojen parantuessa. Tämä tulee lisäämään tautitaakkaa 
yhteiskunnalle, ja näin ollen terveydenhuollon resurssien tehokas kohdentaminen on tärkeää. 
 
Terveyteen liittyvän elämänlaadun (HRQoL) tutkimus eturauhassyövässä on yleistymässä, mutta 
kirjallisuuden perusteella preferenssipohjaisten indeksimittareiden, jotka tuottavat terveyden tiloihin 
sidottuja hyötyjä (utiliteetteja), tai joita voidaan käyttää laatupainotettujen lisäelinvuosien (QALY) 
määrittämiseen, on vähäistä. Tämä on ongelmallista, koska elämänlaatuarviot ovat olennainen osa 
kustannus-hyötyanalyysiä, jota voidaan pitää nykyään tarkoituksenmukaisimpana 
analyysimenetelmänä terveystaloustieteessä. 
 
Tämän tutkimuksen yleisenä tavoitteena oli tutkia terveyteen liittyvää elämänlaatua ja kustannuksia 
eturauhassyövän eri vaiheissa. Tarkoituksena oli tuottaa tietoa, jota voidaan käyttää 
terveystalousanalyysien tuottamiseksi. Terveyteen liittyvää elämänlaatua arvioitiin yhdellä 
syöpäspesifisellä (EORTC QLQ-C30) ja kahdella geneerisellä (EQ-5D-3L ja 15D) elämänlaatumittarilla. 
EQ-5D-3L sisälsi myös visuaalisen mittarin (VAS). Kustannuksia arvioitiin lisäkustannuksina potilaille 
haettujen ikä-, sukupuoli- ja asuinpaikan mukaan vakioitujen vertaisarviointien perusteella. 
 
Tutkimukseen kutsuttiin yhteensä 1025 eturauhassyöpäpotilasta, joista 630 (61,5 %) osallistui 
tutkimukseen. Potilaat kerättiin poikkileikkausotoksena Helsingin ja Uudenmaan sairaanhoitopiiristä. 
Eturauhassyöpäpotilaiden tiedot koottiin osana laajempaa tutkimusta, jossa samankaltaisia tietoja 
kerättiin myös paksusuoli- (CRC) ja rintasyöpäpotilailta (BC). Eturauhassyöpäpotilaiden ikäjakauma 
vaihteli 44-vuodesta 93-vuoteen, useimmilla heistä oli paikallinen sairaus, he olivat naimisissa tai 
avoliitossa ja heillä oli korkeakoulutus. Potilaat jaettiin viiteen toisensa poissulkeviin ryhmiin, jotka 
perustuivat syövän eri tiloihin: Primaari (paikallinen sairaus, kuusi kuukautta diagnoosin jälkeen), 
Rehabilitation (paikallinen sairaus, 0,5 - 1,5 vuotta diagnoosin tai toistumisen jälkeen), Remission 
(paikallinen sairaus, yli 1,5 vuotta diagnoosista), Metastatic (metastaasien havaitsemisen jälkeen) ja 
Palliative (ilman kemoterapiaa ja sädehoitoa sekä potilaita, jotka kuolivat syöpään kuuden 
kuukauden sisällä).  
 
Kaikki arvioidut elämänlaatumittarit antoivat arvokasta tietoa potilaan terveyteen liittyvästä 
elämänlaadusta. 15D elämänlaatumittarin arvot vaihtelivat välillä 0,344 – 1,000 (keskiarvo 0,863), 
EQ-5D: -0,166 – 1,000 (keskiarvo 0,845) ja VAS: 1 - 100 (keskiarvo 76,4). 30 potilasta arvioi olevansa 
täydellisessä terveydentilassa (5 %) käyttäen 15D- ja VAS-mittaria, kun taas EQ-5D-3L mittari tuotti 
jopa 266 (42 %) potilaalle vastaavan tuloksen. Terveyteen liittyvä elämänlaatu pysyi suhteellisen 
korkealla tasolla, kunnes sairaus eteni. Tärkeimmät elämänlaatua laskevat selittävät tekijät olivat 
väsymyksen ja kivun oireet sekä taloudelliset ongelmat ja korkea ikä. 
 
Nykyinen tietämys potilaan kokemasta elämänlaadusta syövän loppuvaiheissa on rajallista. Tässä 
tutkimuksessa tavoitettiin 311 palliatiivista syöpäpotilasta ja näistä 114 (37 %) osallistui 
tutkimukseen. Palliatiivisessa hoidossa oleva potilasjoukko sisälsi 30 eturauhassyöpäpotilasta, 57 
paksunsuolensyövän- ja 27 rintasyöpäpotilasta. Keskimääräiset elämänlaatuarvot palliatiivisilla 
potilailla vaihtelivat suuresti riippuen käytetystä elämänlaatumittarista: 15D tuotti korkeimmat arvot 
(keskiarvo 0,74), jota seurasivat EQ-5D-3L (0,59) ja VAS (55,0). Palliatiivisten 
eturauhassyöpäpotilaiden keskimääräiset elämänlaadun arviot olivat puolestaan 0,67 käyttäen 15D 
mittaria, 0,59 EQ-5D-3L-mittarilla ja 48,7 VAS-mittarilla. Palliatiivisessa hoidossa olevista potilaista 
käyttäen EQ-5D-mittaria 13 % potilaista oli täydellisessä terveydentilassa (EQ-5D-3L-pisteet 1,00). 
 
Eturauhassyövän taudin tiloihin liittyvät suorat kustannukset olivat merkittäviä. Kustannuksia 
arvioitiin syövän aiheuttamina lisäkustannuksina kuuden kuukauden ajanjaksoina ja ne sisälsivät 
suorat sairauskulut, tuottavuuden menetykset ja epävirallisen hoidon kustannukset. Resurssien 
käyttö- ja kustannustiedot noudettiin eri rekistereistä, ja lisäksi potilaat vastasivat taustakysymyksiin 
epävirallisesta hoidosta, työkyvystä ja koulutustaustasta. Syövän aiheuttamien lisäkustannusten 
analysoimiseksi jokaiselle potilaalle poimittiin kaksi ikä, sukupuoli ja asuinpaikka vakioituja verrokkeja 
Kansaneläkelaitoksen rekisteristä.  
 
Eturauhassyövästä johtuvat kustannukset erosivat selvästi tautitilojen välillä. Keskimääräiset 
terveydenhuollon välittömät kustannukset kuuden kuukauden jaksoina eri tautitiloissa olivat: 
Primary 2750 €, Rehabilitation 1143 €, Remission 760 € ja Metastatic 7423 €. Suurin osa potilaista oli 
työelämän ulkopuolella, mikä oli odotettavissa keskimääräisen korkean iän perusteella. Potilaista 102 
(16,7 %) oli työssä, ja 430 eläkkeellä olevasta potilaasta yli kaksi kolmasosaa oli 65 vuotta täyttäneitä 
ja siten valtioneläkkeeseen oikeutettuja. Vain 18 (2,9 %) potilasta oli saanut syöpään liittyvän 
työkyvyttömyyseläkkeen ja 28 potilasta (4,6 %) oli saanut työkyvyttömyyseläkkeen muusta syystä. 17 
potilasta (2,8 %) ilmoitti olevansa työssä tai työttömänä. 
 
Sairauspoissaoloista johtuvien menetettyjen työpäivien määrä oli suhteellisen alhainen, keskimäärin 
alle yhden päivän kuuden kuukauden aikana, kun taas varhaiseläkkeestä johtuva työstä poissaoloaika 
oli huomattavasti korkeampi. Yhdistetty työstä poissaolo oli suurinta Primaari- (8,2 päivää) ja 
Metastatic-ryhmissä (12,5 vrk) ja alhaisimmillaan Rehabilitation- ja Remission- ryhmissä, 5,4 ja 4,0 
vuorokautta. 
 
Menetykset tuottavuuskustannuksina olivat korkeimmat (4277 €) edenneessä taudissa. Kaiken 
kaikkiaan epäsuorien kustannusten osuus kokonaiskustannuksista oli noin kolmasosa. Yhdistäen 
tuotannonmenetyksen ja epävirallisen hoidon kustannukset, niiden yhteenlaskettu osuus 
kokonaiskustannuksista nousi noin puoleen tai hieman yli. Potilaan läheisten antaman 
keskimääräinen epävirallisen hoidon määrä oli vaatimaton noin tunnin tai vähemmän viikossa, ja vain 
34 potilasta (5,6 %) ilmoitti saaneensa sitä. Tutkimustulosten perusteella tuottavuuden menetykset 
ja epävirallisen hoidon kustannukset voivat olla merkittävässä roolissa arvioitaessa eturauhassyövän 
kokonaiskustannuksia. Näiden kustannusten huomioitta jättämisellä voi olla merkittävä vaikutus 
taloudellisten arvioiden tai HTA:n lopputulokseen ja täten mahdollisiin resurssikohdennuspäätöksiin. 
 
Tutkimuksessa analysoituja geneerisiä elämänlaatumittareita (EQ-5D-3L ja 15D) ei tulisi käyttää 
taloudellisissa arvioinneissa suoraan keskenään vaihdettavina etenkään silloin, kun elämänlaatuarvot 
ovat alhaiset tai eroavat huomattavasti ikävakioitujen vertaisten tasosta. EQ-5D-3L tuottaa 
suurempia eroja kuin 15D. Tämän tutkimuksen tulokset tukevat osaltaan joitain jo aiempia 
tutkimuksia, kuten EQ-5D-mittarin korkean kattoefektin, kaksihuippuisen, epäjatkuvan tulosten 
jakauman sekä 15D-mittarin tuottamat korkeammat elämänlaatuarvot verrattuna EQ-5D-3L-
mittariin. Nämä erot on syytä ottaa huomioon valittaessa ja käytettäessä näitä mittareita sekä 
varsinkin analysoitaessa niiden tuottamia tuloksia. 
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European health care systems are struggling with challenges on how to fund health care with ever 
raising needs of the patients. Scientific evidence based on health economic evaluations has been 
introduced to enable decisions-makers to make informed decisions on resource allocation. The use of 
health economic evaluations has increased with the aim of making the best possible use of limited 
health care resources (Drummond et al 2005).   
Health economics is a discipline under the umbrella of economics. Health economics usually deals 
with issues related to efficiency, effectiveness, value, equity and behaviour in the production and 
consumption of health and healthcare. Some of the topics in this dissertation could be also linked to 
pharmacoeconomics, which is a multidisciplinary discipline interested in the clinical and economic 
aspects of pharmaceuticals within the health care systems or society and uses methods originating 
from health economics.  
Prostate cancer (PC) is the most common non-skin cancer in men and the third most common cause 
of cancer deaths in men in Western Europe. In 2012, an estimated 1.1 million men worldwide were 
diagnosed with PC, accounting for 15% of the cancers diagnosed in men (Ferlay et al 2013). Most 
cases (around 70%) are diagnosed in more developed regions and the burden of PC is remarkable 
both in economic and clinical respects.  
During the last few decades, increased attention has been focused on cancer patients’ health-related 
quality of life (HRQoL), but so far the understanding of patients’ HRQoL and costs of care throughout 
the disease pathway from early diagnosis to the terminal stages of cancer is still limited. This is partly 
explained by the fact that generic HRQoL instruments that can be used for cost-utility analysis, the 
state-of-the-art method of health economic evaluation, have only seldom been used among PC 
patients. This study aimed to collect this type of evidence to support cost-utility analyses in PC. 
For the comparison of the results from health economic evaluations, a key question is to know 
whether different HRQoL instruments produce similar results. If they do not, it may have a significant 





2. BACKGROUND AND REVIEW OF THE LITERATURE 
 
 Prostate cancer 2.1
Prostate cancer (PC), also known as carcinoma of the prostate, is the development of cancer in the 
prostate, a gland in the male reproductive system. In contrast to the current situation, PC was 
initially considered a rare disease, probably because of shorter life expectancies and poorer 
detection methods in the 19th century (Lytton 2001). 
Today PC is the fourth most common cancer in both sexes combined and the second most common 
cancer in men after skin cancer. PC accounts for 15% of the cancers diagnosed in men (Bray et al 
2013). Factors that increase the risk of PC include: older age, a family history of the disease, and race, 
as African American men are approximately 70% more likely to develop prostate cancer in their 
lifetime than Caucasian or Hispanic men. About 99% of cases occur in those over the age of 50. 
Having a first-degree relative with the disease increases the risk two- to threefold. Other factors that 
may be involved include a diet high in processed meat, red meat, or milk products or low in certain 
vegetables (World Health Organization 2014). Studies of twins in the Nordics countries suggest that 
around half of PC risk can be explained by inherited factors (Mucci et al 2016).  
Due to risk factors, the incidence of PC is higher in developed countries than in the rest of the world. 
In fact, the incidence of PC varies more than 25-fold across the world; being highest in Australia/New 
Zealand, Northern America and in Western and Northern Europe, because the practice of prostate-
specific antigen (PSA) testing and subsequent biopsy has become widespread in those areas (Bray et 
al 2013).  
Therefore, a majority of those with PC will, due to their advanced age at diagnosis, die of other 
causes without suffering significantly from PC. Also, PSA testing has a much greater effect on the 
incidence than on mortality; there is less variation in mortality rates worldwide (ten-fold) than is 
observed for incidence, with the number of deaths from PC being larger in less developed than in 
more developed countries (Bray et al 2013). 
The time between screen detection (PSA testing) and clinical detection of a cancer is called lead time, 
which is an important concept for early detection of cancer. Long lead times may lead to over-
diagnosis, and conversely with short lead times, it can be difficult to ensure that screening takes 
place in the short window between when a cancer is first amenable to screen detection and when it 
is detected clinically. In a recent Swedish study, men with a longer lead time between elevated PSA 
and subsequent prostate cancer diagnosis were more likely to have high-grade cancers at diagnosis 
(Assel et al 2018). This finding supports the grade progression hypothesis, whereby PC followed over 
time exhibits a transition from benign to low-grade and then to high-grade cancer. However, it is not 
possible to know whether a given low grade lesion becomes high-grade cancer, or whether a new 
high-grade focus arises in a prostate that already contains a low-grade cancer. 




Most PCs are slow growing; however, some grow relatively quickly. The cancer cells may spread from 
the prostate to other parts of the body, particularly the bones and lymph nodes. PC may initially 
cause no symptoms, however in later stages it can lead to difficulty in urinating, blood in the urine, or 
pain in the pelvis, back or when urinating. Other late symptoms may include feeling tired due to 
anemia (World Health Organization 2014). 
 
Incidence and prevalence in Finland 
In 2015, 4,855 new PC cases were diagnosed in Finland (Finnish Cancer Registry 2016). It was the 
most frequently diagnosed cancer in men in Finland accounting for 29% of all the cancers diagnosed 
in men. The incidence of PC has been steadily rising over the years and the annual number of new 
diagnoses has doubled over the last 50 years. This has been mainly driven by more advanced 
diagnostic methods and aging of the population. In the beginning of year 2015, there were 47,500 
men living with diagnosed PC (ICD code C61) in Finland. In year 2015 PC caused 921 deaths, being the 
second most common cause of cancer deaths (14.0%) in men after lung cancer. The PC incidence is 
expected to increase up to approximately 6,400 cases and slightly over 1,000 PC deaths by year 2020 
(Ferlay et al 2013).  
 
Screening and diagnostics of prostate cancer 
Early PC is usually a non-symptomatic disease, or if there are symptoms, they are similar to those 
caused by benign prostatic enlargement. Most cases are found during screening with a PSA blood 
test, or sometimes with a digital rectal exam (DRE), but the actual diagnosis can only be made with a 
prostate biopsy. In the DRE the examiner inserts a gloved, lubricated finger into the rectum to 
examine the adjoining prostate. The PSA blood test measures the concentration of this molecule in 
the blood. PSA testing was introduced to evaluate treatment response in late 1980s, but was soon 
widely adopted for screening (Hayes & Barry 2014). 
Finnish researchers have participated in the European Randomized Study of Screening for Prostate 
Cancer (ERSPC) trial to evaluate the impact of PC screening on mortality. Based on the results of 
262,000 people during a nine-year follow-up, it seems that PSA testing reduces deaths from PC by 
one fifth (Schröder et al 2009). Of the Finnish participants (80,000) of the trial, 30,000 were 
randomized to have PSA testing at the age of 55-71 years 2-3 times at four-year intervals. The 
remaining men formed the control group. The incidence of PC in the screening arm was 8.8 per 1,000 
person-years and in the control arm 6.6. PC mortality among the Finnish participants did not differ in 
a statistically significant manner between the arms and to avoid one PC death, around 1,200 men 
needed to be invited to screening and 25 PC cases detected. The Finnish study group concluded that 
a relatively conservative screening protocol produced a small PC-specific mortality reduction, 
however statistically not significant, in the Finnish trial, at the cost of moderate over-diagnosis 
(Kilpeläinen et al 2013).    
The biggest benefit of screening is definitively its ability to detect PC at an early stage, when it can 
still be cured. In line with that, many more PCs were detected in the screened group than in the 
control group in the ERSPC study. Similar findings have also been reported in some other studies 
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indicating that not all early stage tumors will ever advance to harmful cancer (Carlsson et al 2015). 
Based on the results, it is not certain whether screening causes more benefit or harm. A Cochrane 
review concluded that PC screening did not significantly decrease PC-specific mortality in a combined 
meta-analysis of five randomized clinical trials (RCTs) (Ilic et al 2013). Only one study (ERSPC) 
reported a significant 21% reduction of PC-specific mortality in a pre-specified subgroup of men aged 
55-69 years. Pooled data demonstrated no significant reduction in PC-specific and overall mortality. 
The most important disadvantage of screening for PC is the detection of indolent cases, i.e., cancers 
that would not have been found without screening and would not have caused any harm during the 
man’s lifetime. Currently it is not possible to differentiate the detectable small, histologically 
malignant, but clinically benign PC from more aggressive forms that would spread and eventually 
cause death (Kilpeläinen et al 2015). Currently the European Association of Urology (EAU) 
recommends not to subject men to PSA testing without counselling them on the potential risks and 
benefits (Mottet et al 2017).  
The total number of PSA tests taken in Finland is unknown. Based on the ERSPC study, 68% of Finnish 
men in the in control arm had at least one PSA test. Out of them, 22.1% received at least one positive 
PSA test, and 9.7% were diagnosed with PC (Kilpeläinen et al 2017). This population can be 
considered to be representative (age range 55-67) for the non-screened male population in Finland 
but the total number of PSA tests taken annually remains unknown. As only opportunistic testing is 
currently used in Finland, further research is needed to reveal what the impact of opportunistic 
testing and that of other reasons is on the development of PC incidence and prevalence. 
 
Treatments 
The treatment decision is made together with the patient according to patient characteristics, cancer 
classification and recurrence risk rate. The decision among treatment choices can be complicated as 
there are many different options, and for some of them long-term effectiveness data are scarce. 
Determining whether the cancer is confined to the prostate is a key factor in choosing the treatment. 
If this is the case, localised treatments aiming to cure the disease are in place, but if the cancer has 
spread, the goal of treatment is more likely to control the cancer rather than to cure it. 
For localised PC, the recommended treatment is active surveillance, radical prostatectomy, radiation 
(+/- hormonal) therapy, or hormonal therapy. Metastatic PC patients are treated with hormonal 
therapy. The aim of treatment for castration resistant metastatic PC patients is to improve HRQoL 
and relieve symptoms (Duodecim 2014). 
The treatment decision in localised PC is affected by risk grading (histopathology and PSA), patient’s 
life expectancy (comorbidities, age, general wellbeing), patient preferences on treatments (e.g., 
potential side effects), and local conditions (distance to treatment facilities, available treatment 
options). In a study comparing active monitoring, radical prostatectomy, and external-beam 
radiotherapy for the treatment of clinically localised PC, at a median of 10 years, PC-specific mortality 
was low irrespective of the treatment assigned, with no significant difference between the 
treatments (Hamdy et al 2016). 
In retrospective analyses radical prostatectomy has gained the most favourable position (Zelefsky et 
al 2010). In moderate and high risk localised PC surgery seems to prolong patients’ expected length 
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of life, but in the low risk group this is not seen. This is probably explained by the very good prognosis 
in this patient group even without active treatment (Bill-Axelson et al 2014; Vickers et al 2012; Wilt 
et al 2012). PC which extends beyond the prostate into the surrounding tissue, into other organs, or 
into distant parts of the body, is called advanced PC. Up to 40% of men with PC develop metastatic 
disease and a large share of them eventually develop resistance to androgen deprivation therapy 
(ADT), and progresses to metastatic castration resistant PC (mCRPC) (Australia Cancer Council 2015).  
Some patients may not need to be treated immediately and instead would like to follow the active 
surveillance approach. This could be a good option if a patient wants to avoid possible side effects 
such as incontinence or impotence for as long as possible, or if the cancer is very small and expected 
to grow slowly.  
Radical Prostatectomy (Laparoscopic, Retropubic, Robotic Radical Prostatectomy) removes the entire 
prostate gland, seminal vesicles and some surrounding tissue as a safety margin. This is usually 
performed for localised disease, but it will not guarantee that the cancer will not appear again.  
Chemotherapy is a standard treatment option in all cancers, and PC is not an exception. 
Chemotherapy is usually used in metastatic disease, when the disease has spread outside of the 
prostate and hormone therapy has failed.  
PC cells usually require testosterone to grow, and lowering androgen levels with hormone therapy 
can stop or slow cancer growth. Most of the PCs are initially responsive to hormone therapy, but 
unfortunately hormone therapy has significant side effects, such as a decrease in sexual desire and 
erectile dysfunction. It is usually recommended as the initial treatment for advanced cancers 
(Heidenreich et al 2014). Hormone therapy can also be administered in sequences based on PSA 
testing and this is called intermittent hormone therapy. 
Radiation therapy uses high-energy radiation and particles to kill cancer cells. The two main types 
used in PC are external beam radiation therapy (3-D Conformal Radiation Therapy, Intensity 
Modulated Radiation Therapy [IMRT], Proton Beam Radiation Therapy, Cyberknife) and 
brachytherapy. External beam radiation therapy is focused from a source outside the body onto the 
area affected by cancer. Patients are treated five days per week over a period of seven to eight 
weeks with each treatment only taking a few minutes. In brachytherapy small radioactive pellets 
(seeds) are implanted into the prostate. The seeds are permanently placed in the prostate for a 
radiation period of weeks or months (permanent seed implant) or they are inserted for relatively 
short period of time and then withdrawn (temporary seed implant). 
Alternative and complementary therapies (Diet, Nutrition, Supplements, Exercise, Stress Reduction, 
Asian Medicine) may be available and can be used to support patients, but evidence on their 
effectiveness is scarce (Rackley et al 2006; Bishop et al 2011; Huebner & Follmann 2013). 
 
Survival 
PC patients’ age-standardised relative survival is high compared to some other cancers, being 99% 
after 1, 94% after 5, and 89% after 10 years (Finnish Cancer Registry 2016). The five-year survival 
rates of PC are in Finland the highest among all European countries (Allemani et al 2015). Life 
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expectancy in advanced PC with metastases is around 2-3 years and the 5-year survival rate is around 
30% (American Cancer Society 2014). In patients with mCRPC life expectancy is 6-18 months and can 
be prolonged by 2-5 months with chemotherapy (de Bono et al 2010; Fizazi et al 2012; Scher 2012; 
Parker et al 2013).  
 
Cost of prostate cancer  
Based on a literature review, most of the studies related to the burden of managing PC have been 
carried out within the United States (US) health care system (Sanyal et al 2013). The literature review 
revealed that there was a lack of methodological consensus (e.g., cost components evaluated were 
inadequately reported), which led to variation in direct costs between studies making comparisons 
difficult (Sanyal et al 2013). Nevertheless, results of economic analyses indicate significant direct cost 
of PC treatments. Direct costs comprise all consumption of resources resulting from a treatment or 
therapy and directly attributable to this. Table 1 illustrates cost estimates for PC from different 
countries. 
 
Table 1. Cost and burden estimates for PC. 
Country 1st year cost 4-5 year cost  Total burden from PC 
per inhabitant 
Italy  €6,6001 €8,5162 €103 
United Kingdom  €3,1712 €5,9842 €73 
Germany  €4,0572 €10,9492 €213 
France  €5,8512 €9,7252 €153 
Spain  €3,2562 €7,7532 €103 
United States  $13,9012   
1 Valued in year 2000.(Lazzaro 2003) 
2 Drug costs are from 2006 and all other costs or charges were either inflated to the year 2006 level using consumer price indexes (France, 
Germany, Italy and Spain) or a health inflation index (UK). The cost of initial treatment over 1 year after initial diagnosis was calculated for 
all patients diagnosed with a specific stage, not only those treated. UK costs were converted to Euro at an exchange rate of £0.79 = €1, as 
of August 2008. (Fourcade et al 2010) 
3 Valued in year 2009, estimated health-care costs consisted of expenditure on care in the primary, outpatient, emergency, and inpatient 
settings, and also drugs. Additionally, costs of unpaid care provided by relatives or friends of patients (i.e., informal care), lost earnings 
after premature death, and costs associated with individuals who temporarily or permanently left employment because of illness were 
included. (Luengo-Fernandez et al 2013) 
 
Even with variation of the results regarding both the 1st year and year 4-5 costs, these results can be 
used to estimate the plausible cost and burden level caused by PC. There has also been an increasing 
interest in evaluating the impact of cancer on employment and thus productivity. Results in Table 1 
(Total burden from PC) are supporting the Sanyal et al (2013) estimate that PC is a significant burden 
on societies. 
 
In Finland, the costs of PC have been mainly studied in the context of other cancers (Mäklin & 
Rissanen 2006; Kalseth et al 2011; Syöpätautien asiantuntijaryhmä 2014). In total, treatments in 
cancer care utilize around 4% of the total health care budget. It has been estimated that in 2004 the 
total cost of managing PC in Finland was €180 Million (M), which was more than double compared to 
the management of breast cancer (BC) (Mäklin & Risssanen 2006). However, since then there have 
been other estimates for the burden caused by cancer care, and results have changed over the years, 
but varied between €750M and €1,500M (for 2020) (Syöpätautien asiantuntijaryhmä 2014). Torkki et 
al 2017 estimated that the total cost of cancer care in Finland in 2014 was €927 Million. 
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In an EU country comparison study from 2009, it was estimated that the health care cost of PC was 
annually €16 per every inhabitant in Finland, which was the third highest share per person after 
Germany and Luxemburg (Luengo-Fernandez et al 2013). The biggest total direct health care cost 
(€88M) drivers in PC in Finland were inpatient care (€38M) and medication (€34M). Other costs 
included primary care €3M, outpatient care €10M, and accident and emergency care €1M. Estimated 
productivity losses due to PC were €11M, which was mainly driven by mortality (€8M) and, to a 
lesser extent, morbidity (€3M) (Luengo-Fernandez et al 2013). The cost of informal care was 
estimated to be €16M annually, and combining both total direct health care cost and productivity 
losses and informal care, this sums up to €114M as a total cost due to PC in 2009 (Luengo-Fernandez 
et al 2013). If Finland is assumed to have 47,500 PC patients, this would result in an average of 
around €2,400 per PC patient. 
Spending on pharmaceuticals has emerged as a frequently discussed topic in public debate as new 
expensive medicines have been developed. Regarding oncology, and more specifically PC 
medications in Finland, more than 10 new medications have entered the market during the last 
decade or so (e.g., docetaxel, cabazitaxel, denosumab, abiraterone, radium -223, enzalutamide). The 
sales of antineoplastic and immunomodulating agents (€423M) grew 11% in 2013, even though the 
wholesale prices of many reimbursable drugs within this group were lowered by 5%. The sales of 
antineoplastic agents (€169M) were up by 4%, the sales of endocrine therapy (€29M) by 32% and the 
sales of immunosuppressants (€170M) by 22%. The sales growth seen in endocrine therapy was 
mainly attributable to the tripling of the sales of abiraterone (€10M) used in the treatment of PC. The 
increase seen in the sales of immunosuppressants was also greatly attributable to the growth seen in 
the sales of new drugs (Finnish Medicines Agency and Social Insurance Institute 2014). In 2015 there 
were 21,093 patients, who were entitled to special refunds due to their PC. The average cost per 
patient was €1,674. However, 643 patients were entitled to gain special refunds to abiraterone and 
enzalutamide, where the average cost per patient was substantial, €28,989 (Finnish Medicines 
Agency and Social Insurance Institute 2016).  
 
 Health-related Quality of life 2.2
 
Health-related quality of life (HRQoL) is an important and broad concept of patients’ experience of 
health. It reflects the physical, psychological and emotional dimensions of health (Gold et al 1996). It 
can be used e.g., to describe general wellbeing of a person, or to assess how disease would impact 
on a person’s HRQoL. Information on HRQoL is also vital to be able to make informed choices about 
treatments for PC, especially since the increased use of PSA testing based screening now exposes 
more patients to the knowledge of their early PC, when there are multiple treatment alternatives to 
choose from.  
During the last three decades the use of HRQoL instruments has become more popular as a 
consequence of general acceptance of an approach to describing health states of individuals in terms 
of multiple domains of health, and in developing self-reporting instruments to seek information 
regarding these. During the same time period there has been a shift in thinking about health 
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conditions: the focus has moved from diagnostic descriptions towards understanding health 
conditions in terms of disabilities, functioning and health states.   
In order to measure and report on the health of populations or individuals we need to develop a 
valid, reliable and comparable way to measure the health status. This requires at least the following: 
a classification of health state domains, specification of a set of domains necessary and sufficient to 
describe health states for measurement purposes, specification of what we are measuring in each 
domain, and a common understanding of what is full health versus exceptional talent in any given 
domain. 
The WHO definition of health notes that health is a multi-dimensional concept (Sadana et al 2000). 
There are potentially three sets of domains that can be specified in order to describe health and 
contribute to a health state description: 1) core domains of health that almost all people agree upon 
as important to the direct measurement of health, 2) additional domains of health that most people 
agree are direct measures of health, but that might not provide important information additional to 
the core domains, and 3) domains that are related to health and might serve as good proxy measures 
of the experience of health  (i.e., those that are indirect measures of health). Potential domains in 
each of these three categories are illustrated in Figure 1, based on an extensive review of existing 
health state measurement instruments and health measurement literature (Sadana et al 2000).  











The items in bold are proposed as the core domains that almost all people agree upon.  
Figure 1 is adapted from Sadana et al 2000. 
 
In this dissertation the concept of HRQoL was studied from the following points of view: 1) studied 
instruments are used in clinical practice, 2) instruments can be used in health economic analysis, 3) 
to have both generic and disease- specific instruments, 4) instruments are self-administered, widely 
used, validated and standardised. From health economic analysis point of view, focus was put also on 
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having generic index based instruments which can be used directly to calculate QALYs for cost-utility 
analysis.  
Following HRQoL instruments were chosen to be used and analysed for this dissertation: disease- 
(cancer) specific EORTC QLQ C30, and two generic (index) instruments 15D and EQ-5D-3L. All these 
instruments are widely used and were considered good candidates to study patients’ HRQoL in 
different states of PC. These instruments can be considered to represent ‘generic’ instruments in 
terms of not having very deep disease specific questions. Of course, the  cancer-specific EORTC QLQ-
C30 will have common cancer-related symptoms questions (e.g., fatigue and vomiting) but not 
specifically PC related questions (e.g., frequent urination, erectile dysfunction) although the generic 
15D covers some of these symptoms (e.g., sexual functioning and excretion). Having different types 
of instruments was also one of the aims: can different types of instrument be used in this setting and 
will they generate results that are similar or different? Having these ‘generic’ instruments may lead 
to a situation that some of disease characteristics (PC-related symptoms) may have been overlooked 
or not emphasized as much as they deserve (compared to PC-specific instruments), although the idea 
was more to focus on HRQoL measurement in general. These instruments would allow HRQoL 
comparison of different diseases in health economic analysis. All studied instruments are also 
covering more or less extensively the WHO’s domains of health. 
HRQoL can be assessed in different ways: there are disease-specific, generic and preference- (utility-) 
based methods. Different levels of problems or dimensions can be described with different disease-
specific or generic instruments.  Disease-specific instruments are used for studying the most 
important effects of a given disease on patients’ HRQoL. However, they are not suitable for 
comparison of different health care interventions across different disease entities. Thus, they are 
useful for providing insights into patients’ symptoms and functionality, and are well suited for clinical 
decision making. Good examples of disease-specific instruments that are widely used to evaluate PC 
patients HRQoL are the 27-item Functional Assessment of Cancer Therapy (FACT-G) scale (Esper et al 
1997), the 12-item prostate cancer-specific tools (FACT-P) scale (Cella et al 1993), the International 
Prostate Symptoms Score (IPSS) (Barry et al 1992), the UCLA Prostate Cancer Index (UCLA-PCI) (Litvin 
et al 1998) and the Expanded Prostate Cancer Index Composite (EPIC) (Wei et al 2000). More 
information regarding disease-specific quality of life instruments can be found from a recent 
systematic and standardised comparison (Schmidt et al 2014). 
The advantage of generic instruments is that they can be used across different patient groups with 
diverse underlying diseases or disabilities. The generic instruments can be classified into two groups: 
profile and single index score instruments. The profile instruments measure, depending on the 
instrument, a broad scale of physical and emotional dimensions. The Short Form 36 (SF-36) (Brazier 
et al 2002), for instance, generates dimensions such as vitality, emotional role functioning, and social 
role functioning. The single index instruments provide a single index score usually between 0 and 1, 
although other scales also exist.  
Utilities, preference weights, quality weights, health state values, all these terms are used 
interchangeably, can be elicited for single index score instruments by direct or indirect valuation 
methods. The aim of the health state valuation is to establish population preferences or so called 
quality weights for the different health states defined by the health state descriptive system. 
Typically, in the direct and holistic approach, the health states to be valued are described in written 
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form to those from whom the valuations are elicited (the respondents) who must imagine 
themselves in those hypothetical states. Using the indirect approach, the valuation is divided into 
parts or stages and the final HRQoL scores for different health states are aggregated from the results 
of those stages.  
 
The most used application using utilities is the quality-adjusted life-year (QALY), which takes into 
account both the quantity and quality of life generated by a health care intervention. The basic idea 
is very simple: a year of life lived in perfect health is worth one QALY, and a year lived in a state of 
less than this perfect health is worth less than one QALY. A QALY places a weight (utility, preference 
weight, quality weight, health state value) on time in different health states typically ranging from 0 
(=dead) to 1 (=perfect health). In order to assess the exact QALY value, the utility value associated 
with a given state of health needs to be multiplied with the time spent in each state. The QALYs 
gained provides a common transferable currency for measuring the extent of health gain that results 
from health care interventions, and when combined with the costs associated with the intervention, 
the relative worth of the intervention from an economic perspective.  
 
The most commonly applied method of constructing QALYs is based on an individual-based approach 
of value measurement, and this can be considered being consistent with the principle of consumer 
sovereignty, the keystone of welfare economics (Weinstein et al 2009). Individual health preferences 
are measured with techniques such as the standard gamble (SG), time-trade-off (TTO), and visual 
analogue scale (VAS) (or rating scale). In TTO respondents are asked to choose between remaining in 
a state of certain health for a period of time, or being restored to perfect health, but with having a 
shorter life expectancy. In SG the choice is between remaining in a state of certain health for a period 
of time, or choosing a medical intervention which has a chance of either restoring them to perfect 
health, or killing them with a certain probability. In VAS, however, persons are asked to rate a state 
of health on a scale from 0 to 100, with 0 representing being dead and 100 representing perfect 
health. This method has the advantage of being probably the easiest to ask. 
The SG is based on well-defined, widely accepted axioms of consistency of preferences under 
uncertainty such as transitivity, independence, and continuity. The TTO has a unique conceptual 
relationship to QALYs, because it tries to measure explicitly a trade-off between the time in an 
impaired health state relative to healthy quality-adjusted time. The TTO is also theoretically 
equivalent to the SG under the conditions in which QALYs are appropriate as a utility, which include 
risk neutrality with respect to longevity. Rating scales (including VAS) have sometimes been 
considered theoretically inferior to SG or TTO (Weinstein et al 2009), but there are problems, both 
theoretical and empirical, with alternative methods as well (Parkin & Devlin 2006). Parkin & Devlin 
(2006) recommend that the selection of the appropriate valuation method should be based on 
empirical performance, and in this the VAS has important advantages. They conclude that there are 
strong grounds for disputing the consensus view against the VAS and challenge those who hold it to 
deploy more convincing arguments and evidence in favour of alternative methods.   
With multiattribute utility instruments (e.g., EQ-5D, HUI2, HUI3, SF-6D, QWB, 15D) the health states 
are valued as a matrix of combinations of health domains (or attributes) which are associated with 
the particular instrument. For instance the 15D has 515 health states which are defined by selecting 
one of 5 levels of health within each of the 15 dimensions. Respondents classify themselves into one 
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of the cells in these matrices. Each of the cells comes with the score that has been previously 
obtained by a survey of respondents of the general public. 
Figure 2 presents a situation where intervention B provides a consistently greater area under the 
time curve than intervention A and the shaded area between the curves represents the QALY gain 
from intervention B in comparison to intervention A. Intervention A QALYs can be calculated as 
follows: k1V1 + k2V2 + k3V3 = QALYA, and QALYs for Intervention B: k4V4 + k5V5 + k6V6 + k7V7 = QALYB. 
QALYs gained for health economic analysis is difference between the interventions: QALYB – QALYA = 
QALYs gained. 
Figure 2. QALYs gained from intervention A in comparison to intervention B. 
 
Figure 2 is adapted from Sintonen (2007). 
 
HRQoL has been extensively studied in PC and over 2000 publications were found to be related to 
HRQoL in PC since 2002 (Torvinen et al 2016b). From a health economic point of view it is striking 
that only a fraction of these studies used preference-based index score instruments and thus 
reported data that can be used for QALY calculations. The choice of the utility instrument has proven 
to have a large impact on the results of cost-utility studies (Stavem 1999; Brazier et al 2004). This is 
impacted by the differences in the health descriptive systems and the methods used to value the 
health states defined by the descriptive system. However, there is no consensus regarding a gold 
standard HRQoL instrument.  
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In a Finnish study, Kuivalainen (2004) studied PC patients’ HRQoL before and during the first year 
after treatment. She used the disease-specific instruments EORTC QLQ-C30 and EORTC Pr25, and the 
generic instruments 15D and EQ-5D. Pain was found to be related to reduction in HRQoL during the 
first four months after treatment, and was related to patients’ reported social function, role function 
and insomnia. Urinary disorders were worse during four months after treatment, and they impair 
HRQoL, especially in terms of insomnia and fatigue. In general, 15D and EORTC correlated 
significantly with each other and both instruments were considered appropriate. 
 
 Cost methods  2.3
 
Costing typically involves identifying, measuring and valuing all resource utilization that occur as a 
certain health care intervention is carried out in order to gain health effect (Brouwer et al 2001). 
Unfortunately it is not an easy exercise to solve the puzzle related finding straightforward method of 
valuation when determine the value of the cost items. For instance societal costs of services provided 
or patient time are not easy to value. Notably health care market is lacking perfect market 
conditions, and prices cannot be considered to reflect opportunity costs, and other methods like 
shadow prices needs be considered. In order to make robust assessment of an intervention, all costs 
and consequences needs to be examined regardless of who bears the burden or where they occur in 
society. 
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O U T C O M E: 




It is relatively rare that in cost of illness (COI) studies all the costs related to disease have been taken 
into consideration (Mäklin & Rissanen 2006). Similarly health economic evaluations are in practice 
using mainly direct medical and healthcare costs. These are generally easier to measure, but 
neglecting indirect costs may lead to an underestimation of the true cost of a disease. Particularly, 
disregarding productivity losses may result in an undervaluation of the disease burden. Informal care 
provided by family members or relatives and friends is an important element of care for many cancer 
patients and, therefore, cost of informal care is recommended to be included in economic 
evaluations. 
 
Direct health care costs 
Direct health care costs usually consist of specialist care/hospital costs including inpatient episodes 
and outpatient visits to secondary health care. Direct health care costs should also include primary 
health care that can include information on general practitioner and nurse visits, home hospice care 
and primary care hospitalisation. Also data concerning the use of private health services should be 
included. The cost of Medicines (outpatient/inpatient) is usually one of the easiest and most precise 
metrics to collect due to the controlled systems regarding reimbursement and dispensing of 
medicines.  
Direct non-health care costs 
There are also directly measurable costs which can be linked to utilization of the health care services 
but are still to be considered direct non-health care costs. For instance Cost of travelling to the 
facilities where treatment is given is sometimes directly measurable, but usually some level of 
estimations and assumptions are needed to calculate these. 
Productivity costs 
From an economic point of view, cancer-related productivity losses emanate from the value of 
production lost due to morbidity and premature mortality. Traditionally, morbidity costs consist of 
the value of production lost due to short-term cancer-related work absences, in addition to 
permanent absence from the workforce before conventional retirement age. Premature mortality 
costs comprise the value of production lost due cancer-related death before conventional retirement 
age. Although it is easy to delineate cost components that are required for the analysis, the 
appropriate method to measure and value the productivity costs associated with disease has been an 
area of considerable debate (Koopmanschap et al 1995; Johanneson & Karlsson 1997; Liljas 1998; 
Zhang et al 2011).   
In the cancer setting, the most frequently used method to estimate productivity losses is the human 
capital approach (HCA) (Tinghög et al 2005; Lidgren et al 2007; Bradley et al 2008). HCA takes the 
societal perspective and counts any hour not worked as an hour lost. By contrast, the other method 
used, friction cost approach (FCA), takes the employer’s perspective and only counts as lost those 
hours not worked until another employee takes over the patient’s work.  
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There are issues in using either of these methods such as higher earning potential valued over the 
low income potential (e.g. young/old/race/educational level etc.). Both methods may also over-
estimate real production losses and they assume that gross earnings reflect real productivity.  
A noted advantage for the HCA is that it can be judged to be credible as it is founded on economic 
theory, although there is also criticism due to the same reason; the neoclassical assumptions 
underpinning the methods are unrealistic. For instance, it assumes full productivity and employment, 
and that labour markets are competitive, and that workplace productivity is assumed to be paid for 
by employers with a wage that is directly proportionate to the employee’s contributions to the firm 
(Tranmer et al 2005). Nevertheless, the HCA is easy to apply and intuitive from an employer 
perspective.  
FCA values production lost due to disease depending on the time-span an organization needs to 
restore the initial production level (i.e., cost of replacing a reduced or disabled working capacity). 
This would require data on whether the work can be completed by an employee with reduced or 
disabled working capacity, frequency of the friction period, and knowledge of the economic cost of 
lost production. This might have an advantage such as a more accurate measure of lost productivity, 
but requires assumptions that are practically impossible in many jobs, such as it assumes perfect 
market for supply of workers (van den Hout 2010). 
Hanly et al. (2012) found in their study, using PC and breast cancer (BC), that result may differ 
substantially between the approaches (i.e., HCA vs FCA). For BC, the FCA total productivity cost 
estimate amounted to 4.2% of the equivalent HCA estimate, whereas in PC, it was 7.5%. In PC, this 
would result in total productivity losses of €109,154 (HCA) and €8,205 (FCA) per patient at the 2008 
price level. The reason for this can be explained by different economic perspectives (i.e., society 
[HCA] vs. employer [FCA]) and time frames associated with approaches (until end of working life; 
long-term [HCA] vs. until worker’s efforts are replaced; short-term [FCA]). Nevertheless, so far there 
is no consensus on this topic and the human capital approach remains the most commonly used 
method (Hanly et al 2012). 
 
Informal care 
Informal care can be defined as care that patients receive free of charge from family members 
and/or friends. Informal care can make up a significant part of the total care provided to care 
recipients with chronic or terminal diseases (Norton 2000). Regardless of this, the costs and effects of 
informal care are often ignored in economic evaluations (Stone et al 2000).  
Informal care costs have been less studied compared to productivity costs, but for instance Buckner 
& Yeandle (2011) reported that alone in the UK the informal care economy is substantial, with almost 
6 million carers in the UK recorded in the 2001 census. For valuation, it is important to recognize that 
informal care is a non-market or quasi-market of services supplied by carers who are often unpaid, or 
who receive only nominal payments or state benefits that do not reflect the true cost or benefits of 
the care (Weatherly et al 2014). Usually informal care is measured by time spent caring, but it is 
difficult to distinguish informal care activities from usual household activities that would be 
undertaken anyway. The time spent on caring can be assigned a monetary value by using a range of 
techniques: revealed preference using the opportunity cost, proxy good or wellbeing valuation 
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method; or stated preference using discrete choice experiments or contingent valuation (van den 
Berg 2004; Koopmanschap  et al 2008; Goodrich et al 2012).  
 
 Economic evaluation 2.4
 
Health economic evaluations of new medicines or other technologies have become common practice 
when they are introduced to health care systems. This assessment can take different forms 
depending on the situation. However, the most frequently used methods are cost-minimization 
analysis (CMA), cost-benefit analysis (CBA), cost-effectiveness analysis (CEA) and cost-utility analysis 
(CUA) (Drummond et al 2005). In CMA the effectiveness of the comparators in question must be 
proven to be equivalent. The preferred 'cost-effective' alternative is simply the one which costs less 
(same outcomes). In CBA costs and benefits are both valued in monetary terms. CEA measures 
outcomes in 'natural units', such as a change in blood pressure (mmHg), symptom free days, or life 
years gained. Finally, CUA measures outcomes in a composite metric of both length and quality of life 
usually expressed as the quality-adjusted life year (QALY) gained.  
Table 2. Different types of economic evaluation methods. 
Method of Analysis Cost Measurement Outcome Measurement 
Cost-minimization Analysis 
(CMA) Monetary (€) Equivalence demonstrated in comparative groups 
Cost-effectiveness Analysis 
(CEA) Monetary (€) Single ’natural’ unit outcome  
Cost-utility Analysis  
(CUA) Monetary (€) 
Multiple outcomes – life of years, adjusted life 
years (QALYs) gained 
Cost-benefit Analysis  
(CBA) Monetary (€) Monetary (€) 
Table 2. Adapted from Drummond et al (2006). 
 
A cost of illness (COI) study is also sometimes classified as an economic evaluation. Yet it is not a true 
economic evaluation as it does not compare the costs and outcomes of alternative courses of action. 
Instead, it attempts to measure all the costs associated with a particular disease or health condition. 
COI studies are, however, important as they try to describe the economic burden of a disease to 
society. These typically include direct costs, indirect costs (the value of lost productivity from time off 
work or diminished ability to work due to illness), and informal care (amount of informal care 
received free of charge from family and friends) costs. Sometimes also intangible costs (the 'disvalue' 
to an individual caused by pain and suffering) have been evaluated.  
 
Incremental cost-effectiveness  
The use of QALYs as an outcome in health economic evaluations has become popular during the last 
three decades. Simply, if there are two interventions to compare, a decision needs to be taken on 
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which one is the better option. The decision can be based on which option is less costly or provides 
better value (e.g., QALYs gained). If one alternative is both less costly and provides better value 
(outcomes), it is a dominant option (strong/strict dominance). In weak (or extended) dominance 
there is another option that is more effective and more costly, but provides better value for money 
(lower incremental cost-effectiveness ratio, ICER). Also, with weak dominance, two options can be 
selected that, when combined, provide strong dominance regarding a third alternative. This refers to 
the ratio of the difference in costs (incremental costs) divided by the difference in outcomes 
(incremental effect) between two alternative interventions. If there are more than two alternatives, 
interventions are compared on a systematic pair-wise basis using their ICERs. The results of a CEA or 
CUA should be reported in terms of ICER (or incremental cost-utility ratio, ICUR). In the simple form 
this means that the cost difference between the interventions (old and new) is divided by the 
difference in HRQoL or QALYs between the interventions as a measure of effectiveness (e.g., 
cost/QALY). 
 




    
 
Many times, in a real world situation, a new treatment is more effective, but also more costly 
compared to standard of care (old therapy). In that case the final decision regarding cost-
effectiveness will depend on the society’s willingness to pay (WTP) for the extra effectiveness (Briggs 
2001). WTP corresponds to the value that the society is willing to invest in an additional health unit 
gained, e.g., QALY. The WTP threshold ultimately determines whether the new intervention is 
regarded as being cost-effective or not. This approach has been criticized for not being fair and 
transparent in all the situations, but evidently fixed thresholds are widely used globally (Grosse 
2008). The maximum threshold varies between countries, for example the National Institute for 
Clinical and Care Excellence (NICE) recommends £30,000, or higher for end-of-life care, and for 
instance in the Netherlands around €20,000 (Health Council 2007) has been mentioned unofficially. 
Many countries have used the WHO recommended approach that an intervention is highly cost-
effective if the incremental cost-effectiveness ratio (ICER) is below the per capita gross domestic 
product (GDP) and cost-effective if it is below 1-3 times GDP (Marseille et al 2015). In Finland the 
decision-makers have not specified an explicit range of threshold values for a cost per QALY gained 
what should be considered cost-effective. Regardless of the debate concerning the right value, it has 
been argued that the threshold lacks an empirical basis and by using only ICER and WTP, equity and 
fairness could be disregarded (Rawlings & Culyer 2004). The latest movement in this debate is that 
Spain announced in early 2017 that they are walking away from using QALYs in their HTA after the US 
and Germany, who did the same earlier. They are considering that QALYs are not methodologically 
and ethically robust enough (Arganda 2017). 
 
Health economic evaluations: case example of PC 
Two most used frameworks in economic evaluations are decision trees and state transition models 
(Karnon 2003, Brennan et al 2006). For illustration on how resource use/cost and HRQoL data can be 
used in PC evaluations, a dummy PC Markov model illustration was developed. Markov models have 
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become a frequently used method in economic evaluations, since they allow researchers to construct 
flexible applications to reflect disease progression using constant, time-dependent, and discrete 
processes (Briggs & Sculpher 1998). These can describe the natural course of diseases (e.g., PC). 
These transitions between ‘health’ states can be graphically represented using a state transition 
diagram shown in Figure 4. Transitions between specified ‘health’ states will occur until all members 
of a hypothetical cohort are moved to the “Death” state.  
 
Figure 4. Markov model in PC illustrated as a state transition diagram. 
 
 
Figure 4. Circles correspond to health states and arrows correspond to possible transitions with associated probabilities from one health 
state to another. 
 
Markov models can have constant probabilities of transitions between states or they may be allowed 
to vary according to another model variable. Two fundamental assumptions behind Markov models 
are that the probability of moving out of a health state is not dependent on the health states that a 
patient may have experienced previously (no memory) and that the health states are mutually 
exclusive (one person only in one point in time or place).  In the PC model presented in Figure 2 that 
would mean that a patient would start from Primary state, stay in that state for 6 months (6 months 
cycle) and after that move to Rehabilitation state or to Metastatic state if metastases are found. 
Again after 6 months in the Rehabilitation or Metastatic states the patient will either stay in that 
state or move on to another state depending on state transition probabilities. The model would be 
run until the end of cycles or as long as all the patients end up in the state “Death”, where it is not 
possible to move anywhere. This model structure could be used to evaluate the impact of screening 
on PC, and the impact of different interventions (e.g., new medicines/operations) introduced in 
Primary




















different states of the disease. In this thesis baseline HRQoL and cost data have been evaluated for 
all these states (excluding screening). In addition to that, the state dependent transition probabilities 
are needed for the analysis. In the simplest case costs and HRQoL could be assumed to be similar in 
two treatments to be evaluated, and the only difference between the treatments would be that in 
the transition probabilities between states (i.e., disease progression probabilities). An example of this 
is a new treatment for localised disease that reduces the probability of moving to metastatic disease 
state. Assuming that there would not be any side effects and HRQoL would remain at a similar level 
and the only things that would change are the cost of the new intervention and improved probability 




3. STRUCTURE AND AIMS OF THE THESIS 
 
The motivation for the empirical study was the rising importance of PC with aging of the population 
and the improved screening and treatment options. Evidence on both cost/resource utilization and 
HRQoL in PC is scarce but such data are needed to perform CUAs throughout the whole treatment 
path starting from screening and early diagnosis all the way to the end-of-life treatment. The aim of 
the empirical studies is to generate data that can be used in CUAs assessing various treatment 
options of PC. Another reason for doing such a study was to gain better understanding for the 
reasons behind resource utilisation and costs, and to identify factors that impact HRQoL in different 
states of PC. By understanding these, it may be possible to emphasize the right things in the 
treatment path and to proactively help patients to undergo treatments. Results are also supporting 
every day clinical decisions on what are the factors potentially influencing patients’ experienced 
HRQoL in different states of PC. 
 
Specific aims for this study were: 
1) to review systematically evidence on the usage of generic, validated HRQoL instruments that 
can be used to calculate QALYs, and consequently are useable directly for health economic 
evaluations in PC; 
2) to measure the PC patients’ HRQoL, by using different instruments, in different states of the 
disease; to compare the HRQoL of patients to that of the age- and gender-standardised 
general population; to compare the results of different instruments and to look for factors 
influencing HRQoL,to compare can they be used interchangeably in health economic 
analyses; 
3) to estimate the real-life costs in different states of PC. Costs include direct healthcare or 





4. MATERIALS AND METHODS 
 
 Patient population and study design 4.1
 
The patient data were collected in the Helsinki and Uusimaa Hospital District that provides specialist 
medical care for the approximately 1.5 million inhabitants of Southern Finland. The study was a 
cross-sectional observational survey approved by the local Ethics Committee (registration number 
207/13/03/02/2008). PC data were collected as a part of a larger study, where similar data were 
collected also for colorectal (CRC) and breast cancer (BC). Patients were enrolled between September 
2009 and December 2010. 
Patients were enrolled in a cross sectional setting and all patients over 18 years of age and diagnosed 
with PC were eligible for the study. A research nurse identified patients from hospital records by date 
of diagnosis based on the tenth version of the International Statistical Classification of Diseases and 
Related Health Problems (ICD-10; PC code C61) as primary or secondary diagnosis. The nurse mailed 
questionnaires to those identified patients who consented to participate. Recently diagnosed 
patients and those receiving only palliative care were enrolled when visiting the hospital. Non-
respondents received one reminder letter. Clinical background information regarding patients’ 
disease stage and treatments administered within the last three months were collected from hospital 
records.  
Patients were divided into five mutually exclusive pre-selected groups based on disease state: 
Primary (local disease, first six months after diagnosis), Rehabilitation (local disease, 0.5 – 1.5 years 
after diagnosis or recurrence), Remission (local disease, more than 1.5 years after diagnosis), 
Metastatic (after detection of metastases) and Palliative care. Palliative care patients were defined 
as patients having metastatic disease and receiving palliative treatments only (defined by no 
chemotherapy or radiotherapy), and patients who died due to cancer within six months of 
responding to the questionnaire, irrespective of the treatment given. These groups were formed 
when the nurse made the initial search to the hospital records based on time of the diagnosis. Some 
patients were moved from the local disease groups to the metastatic or palliative group if the disease 
had progressed. 
Unfortunately it was not possible to perform non-responders analysis. There were no access to 
patient records when patient did not want to participate and therefore consent to have access to 
patient records were not permitted. Only analysis on patients’ age was possible and there was no 
difference between responders and non-responders (69.4 vs 68.2, respectively).  
Patients’ background information was collected simultaneously with questionnaires, which covered 
details regarding marital status, education, occupational status, treatments received outside 
hospital, and informal care. Utility scores were compared to scores from the general population 
obtained in the representative Finnish Health 2000 Health Examination Survey (Aromaa & Koskinen 
2004). The set of questionnaires covered a relatively wide range of topics over 10 pages with a total 
of 76 mostly multiple-choice questions (Appendix 1). 
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 HRQoL Instruments 4.2
 
Two generic self-administered HRQoL instruments were used: the 15D and the EQ-5D-3L (with VAS), 
as well as the cancer-specific EORTC QLQ-C30 questionnaire. All instruments are widely used, 
validated, and standardised.  
 
15D 
The development of the 15D started almost 40 years ago with the idea of combining the advantages 
of a profile and a preference-based measure. The conceptual basis for the health state descriptive 
system was based on the definition of health by the World Health Organisation (WHO), and the first 
15 dimensional 15D with a health state descriptive system came out 1986. Based on the feedback 
received, this version included three new dimensions (depression, distress and pain) in addition to 
the 12 dimensions of the earlier released instrument (Sintonen 1981; Sintonen & Pekurinen 1989; 
Sintonen & Pekurinen 1993). The suitability of this instrument regarding its ability to reflect HRQoL 
was tested among nearly 3,000 individuals and after revisions an updated version was launched in 
1992. In this version, the ability to work and social participation were combined into one dimension, 
labelled “usual activities” and a new dimension on sexual activity was added. In addition, all 
dimensions were changed to five-level scales in order to increase sensitivity.  
The present 15D is a generic instrument with 15 dimensions (mobility, vision, hearing, breathing, 
sleeping, eating, speech, excretion, usual activities, mental function, discomfort and symptoms, 
depression, distress, vitality, and sexual activity). Each of the dimensions has 5 answering levels 
(1=best level; 5=the worse level) of which a person chooses the one that best describes his/her state 
of health at that moment. The 15D can result in 515 possible combinations of describing different 
health states.  
The valuation (indirect) of the 15D is based on an application of the multi-attribute utility theory. A 
set of utility or preference weights, acquired from representative samples of the general public 
through a 3-stage valuation procedure, is used in an additive aggregation formula to generate the 
utility score, i.e., the 15D score (single index) over all the dimensions. In short, during the first stage, 
relative importance weights were elicited from the top levels of the 15 dimensions. At the second 
stage, importance weights were elicited from the lowest levels (5) of the dimensions. The valuation 
procedure was completed using a 0–100 ratio scale (VAS scale) (100=the most important, 0=not 
important at all). The ratio scale nature of the valuation task was emphasized by placing nine arrows 
to the right-hand side of the 0–100 scale with a text explaining how the number pointed by an arrow 
should be interpreted over the range of the scale. For example, if an arrow is pointing to 90, it should 
be interpreted as 90% as important as the most important attribute. The importance weights for the 
intermediate levels were extrapolated linearly from the weights of the extreme ends in relation to 
the distance between level values, which were elicited for each dimension during the third stage. On 
top of the five levels, the states “unconscious” and “dead” were valued on for every dimension. The 
preference weight for each level was calculated by multiplying the level weight by the importance 
weight for the dimension. The most important dimensions for good HRQoL are mental function (i.e., 
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to be able to think clearly and logically), to be able to breathe normally and, to be able to perform 
usual activities (such as work, leisure and hobbies) normally.  
The 15D index score ranges from 0 (=being dead) to 1 (=full health). The minimal clinically important 
difference (MID) in the 15D has been estimated at 0.015 (Alanne et al 2015). The 15D is available in 
more than 30 languages and has been widely used in many different diseases. Based on the 15D, 
there is also available the 16D for adolescents aged 12-15 years and the 17D for children aged 8-11.  
 
EQ-5D-3L 
The EQ-5D-3L was initially developed simultaneously in Dutch, English, Finnish, Norwegian and 
Swedish by The EuroQol Group. The EuroQol Group was established 1987 and it comprised a network 
of international, multilingual, multidisciplinary researchers, originally from seven centres in England, 
Finland, the Netherlands, Norway and Sweden (Euroqol 2017). The main purpose of the Group was 
to explore, whether the health state valuations are similar across a number of European countries. 
To this end a simple health state descriptive system (questionnaire) was created, a set of standard 
health states was derived from the system, and a way of valuing these states in a postal survey (using 
a VAS “thermometer”) of a representative population sample drawn in a standardised way was 
devised.  
The first health state descriptive system of the EQ-5D-3L was developed through a conceptual 
process on the basis of the available HRQoL instruments. Reviewed instruments represented both 
generic and profile instruments (e.g., the Quality of Well-Being Scale, the Rosser Index, and the 15D) 
(Coast 1992; Coons et al 2000; Sintonen 2001), whereas some were simple profile instruments (e.g., 
the Sickness Impact Profile, the Nottingham Health Profile and the Health Measurement 
Questionnaire) (Cole et al 1994).  
 
The first version consisted of six dimensions (mobility, self-care, main activity, social relationship, 
pain and mood) with two to three levels on each dimension. The levels of the dimensions were on a   
scale (The EurQol Group 1990). On the basis of experiences and experiments, a new version was 
ratified in 1991. The dimension social relationships was excluded, and all remaining five dimensions 
were changed to include three levels (84). The names of dimensions were also partly changed and 
are now mobility, selfcare, usual activities, pain or discomfort, and anxiety or depression (The 
EuroQol Group 1990; Brooks 1996). The respondent chooses from these three levels (no problems, 
some problems, extreme problems) based on their perception of health today.  
 
Originally the Group agreed to use a VAS “thermometer” to elicit valuations for generating a single-
index score for the health states defined by the EQ-5D descriptive system. In the VAS valuation 
system, the end points of the scale are the best imaginable (=100) and the worst imaginable (=0) 
health state. In the VAS valuation process, respondents draw a line from boxes describing different, 
earlier defined health states on the scale (“thermometer”) to indicate how good or bad the status is.  
 
The main conclusion from the valuation studies carried out to meet the Groups original purpose was 
that “there appears to be a considerable degree of agreement between health state valuations in 
studies from several European countries, with the exception of Spain” (Sintonen et al. 2003). The EQ-
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5D-3L thus created was not intended to be used as a stand-alone instrument, but to complement 
other HRQoL measures and to facilitate the collection of a common data set for reference purposes 
(Brooks 1996). 
 
The original idea of not regarding EQ-5D-3L as a stand-alone instrument was abandoned, when the 
English participants, primarily from the University of York, decided to carry out an extensive 
valuation study (so called MVH study) using the time trade-off (TTO) valuation method. In the TTO 
method, the respondents choose between two alternatives: x years in full health or a previously 
defined number of years (e.g., 10) in the health state being valued, i.e., how much of the lifetime the 
respondent is willing to sacrifice in order to achieve a higher quality of life. In the MVH study 43 of 
the 243 possible health states were valued by 3,337 respondents of the general UK population. Each 
respondent valued 11 different health states varying from very mild to severe health states. In 
addition to perfect and worst possible health state, immediate death and unconsciousness were 
valued. The respondents completed the health states valuation differently for health states 
considered better and worse than death (Dolan 1997). The valuations for these 43 health states were 
used to create a regression model to interpolate an index score for the rest of health states. The 
scale of the index score is -0.594 to 1 (with the UK TTO tariff), where 1 indicates full health and 0 
represents death. The EQ-5D-3L tariff varies between countries — e.g., in the United States, the 
lowest utility score in the original D1 tariff is -0.102, while in Spain, the lowest is -0.654 (Heijink et al 
2011). All of these tariffs have been based on mean TTO valuations. However, a new tariff (-0.81 to 1) 
based on median TTO valuation has been recommended for use in the United States (Shaw et al 
2013). The different scale lengths achieve that the results of applications from these countries are 
not comparable. We used the UK TTO tariff and in addition we report the scores of patients’ global 
assessments of their health status using the above mentioned VAS “thermometer”. 
In a comparison, the TTO produced higher utility weights compared to VAS in mild and moderate 
health states and considerably lower utility weights in severe health states (Brazier et al 1999). For 
the QALY calculations and cost-utility analyses, it has been recommended that the EQ-5D scores 
defined by the TTO method should be used (Rabin & de Charro 2011).  
 
The EuroQol Group has not estimated MID for the EQ-5D-3L, however, it has been investigated by 
using anchor- and distribution-based methods. Depending on the patient group, the anchor-based 
MID varied from -0.011 to 0.139 and the distribution-based MID ranged from 0.11 to 0.17. For the 
entire patient population, the mean MID was 0.074 and the median MID 0.081 when estimated using 
the anchor-based method (Walters & Brazier 2005). For cancer patients, by using same the methods, 
MID has been estimated to vary from 0.08 to 0.10 (Pickard et al 2007). The EQ-5D-3L has certain 
characteristics that may hinder the proper evaluation of MID, such as a high ceiling effect (i.e., many 
patients reach a score of 1 = perfect health), no scores between 0.88 and 1.00, and non-normal and 
discontinuous distribution of the scores divided into two distinct groups (Saarni et al 2006; Vainiola 





Comparison of the generic HRQoL instruments   
There has been increasing interest in which HRQoL instrument should be used. The instruments can 
be characterised and compared in terms of several aspects. Probably the most important feature is 
the sensitivity of an instrument. This can be evaluated from two perspectives; firstly, ability to 
distinguish differences between individuals and groups in different health states cross-sectionally 
(discriminatory power), and secondly, ability to detect changes in individuals or groups over time 
(responsiveness to change in health status). Discriminatory power can be evaluated by the ceiling 
and floor effects. Furthermore, the properties of the distribution of the scores—e.g., skewness and 
peakedness—can reveal something about the discriminatory power (Sintonen 1994). The ceiling and 
floor effect and skewness can also give some hints about the instrument’s responsiveness to change.  
 
The EQ-5D and the 15D have been compared among patient groups in multiple diseases, and in 
general, the mean utility scores have been higher for the 15D than for the EQ-5D with the differences 
tending to be larger when the utility values are low. The 15D has been shown to be more sensitive in 
detecting change in HRQoL and in discriminating different health states than the EQ-5D (Saarni et al 
2006; Kontomodipoulos et al 2012). Although various instruments are available to measure HRQoL in 
PC, evidence does not indicate whether it is preferable to use generic or disease-specific instruments 
individually, or in combination. As there is a debate regarding the use of disease-specific versus 
generic instruments for assessing HRQoL in PC, the HRQoL results obtained with the cancer-specific 
EORTC QLQ-C30 instrument were also evaluated in this study. 
 
EORTC QLQ-C30 
The cancer-specific EORTC QLQ-C30, developed by the European Organisation for Research and 
Treatment of Cancer (EORTC, founded 1968), assesses the quality of life of cancer patients. It has 
been translated and validated into 81 languages and used in more than 3,000 studies worldwide. A 
first generation of the EORTC instrument came out 1987 (EORTC QLQ-C36) (Aaronson et al 1991). 
The EORTC QLQ-C30 version 3.0 is the most recent version. It came out in December 1997 and should 
be used for all new studies.  
The cancer-specific EORTC QLQ-C30 has a question on a global health status and yields five 
functioning scales (physical, role, social, emotional, and cognitive functions). Fatigue, 
nausea/vomiting and pain are presented on their own scales, as are six single symptom items 
(dyspnoea, insomnia, appetite loss, constipation, diarrhoea and financial difficulties). The EORTC 
produces symptom and functioning profiles, but not utility values. EORTC QLQ-C30 scoring is 
straightforward and each of the multi-item scales includes a different set of items. All of the scales 
and single-item measures range in score from 0 to 100, where a high scale score represent a higher 
response level (e.g., higher level of functioning). In practice, the first step in scoring is to estimate the 
average of the item that contributes to the scale (i.e., raw score) and the next step is to use linear 
transformation to standardise the raw score so that the score ranges between 0 and 100. (Aaronson 
et al 1993; Fayers et al 2001) 
The questionnaire has a 1-week time frame (i.e., “during last week”) and uses a four-point response 
format (‘‘not at all,’’ ‘‘a little,’’ ‘‘quite a bit,’’ and ‘‘very much’’), with the exception of the global 
Health Status scale, which has a seven-point scale. For the functioning and the QL scales, a higher 
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 Literature review on HRQoL (IV) 4.3
 
The objective of the systematic literature review was to identify and qualitatively describe published 
studies  that collected PC patients’ HRQoL estimates by using validated generic instruments which 
can be used to estimate QALYs. 
 
Literature Search 
Computerized literature searches were performed without language restrictions using prostate 
cancer and quality-of-life as key words according to Medical Subject Heading (MeSH) terminology. 
Systematic literature searches were conducted on March 16th, 2013 for the years 2002-2013 and on 
June 18th 2015 for the years 2013-15 from the Medline, Cochrane Library, PsycINFO, and CINAHL 
databases. Furthermore, the most recent, not yet indexed publications were manually searched 
among the Pubmed in Process references. The searches were restricted to meta-analyses, systematic 
reviews, randomized controlled trials, and observational studies. Congress abstracts were not 
included, but systematic reviews and meta-analysis were included for manual double check that all 
the relevant publications were covered. The results in Medline were filtered with the filters 
developed by SIGN (Scottish Intercollegiate Guidelines Network). In addition, bibliographies of 
potential articles that, e.g., included HRQoL/utility data as inputs of cost-effectiveness analyses were 
reviewed manually by the researchers. 
Inclusion criteria 
Initial screening of the identified articles was based on their abstracts, which were reviewed 
independently by at least two of the researchers and selection of relevant articles was agreed on in 
discussion between the reviewers. When an abstract did not give sufficiently precise information 
about the study, or such information was not available at all, the full article was obtained for further 
review.  
Full-text articles obtained for closer evaluation were read independently by at least two of the 
researchers. Included were those articles in which HRQoL data were collected from PC patients, 
results were reported as single index utility scores, and validated HRQoL instruments were used 
(either direct valuation using TTO, SG, VAS, RS or indirect valuation by 15D, EQ-5D, SF-6D, HUI, AQoL, 





 Costs (III) 4.4
 
Costs were estimated as incremental costs due to PC for a six-month period and they included direct 
health care costs, productivity costs and costs of informal care. Resource use and cost data, 
irrespective of who the payer was, were retrieved from various registries in the Helsinki area in 
Finland. In addition, patients answered background questions concerning informal care, work 
capacity and educational status. Patients were divided into groups as explained earlier. 
For every study patient, two control subjects were extracted from the Social Insurance Institution’s 
(SII) electronic records. The control group subjects were standardised for age, gender and place of 
residence. Costs other than those incurred by specialist care were compared against a control group 
and reported as incremental costs related to PC for a six-month period. The sample extracted from 
SII registries covered outpatient medication, sickness allowances and use of private health care. All 
costs are presented at the 2010 price level. 
 
Direct health care costs 
Specialist care. Specialist care data include inpatient episodes and outpatient visits to secondary 
health care. These retrospective data also included inpatient medicines. All secondary care visits that 
were not deemed, by an experienced clinician, to be related to PC treatment were thus excluded. All 
the data, including cost data, came from the hospital’s electronic records, and can be considered 
comprehensive. Costs of travel to treatment were available from the SII records when they exceeded 
the maximum co-payment for the patient (€14). 
Primary health care. Primary health care in Finland is funded and organised by municipalities. 
Primary health care services are available for all residents in the municipality and services are free for 
patients with the exception of some user fees. Primary care data were collected from the three 
largest cities in the catchment area of the hospital, Helsinki, Espoo and Vantaa, covering more than 
80% of study patients. The primary care data included information on general practitioner and nurse 
visits, home hospice care and primary care hospitalisation. Data concerning the reasons for the visits, 
however, remained unavailable. To estimate the proportion of visits that were related to PC, a 
background questionnaire was used to identify the share of primary care visits that were cancer-
related. For patients, whose home municipality was different than any of those mentioned earlier 
(n=100; 15.9% of the patients), missing primary care costs were imputed by using average cost from 
the same disease state. Travelling costs related to PC visits were also included. 
Private health care. Data on the use of private health care services were available from SII’s 
registries. However, these data only cover the part of private health care usage, which the SII has 
reimbursed to the patients. The costs of visits related to PC were estimated as those that exceeded 
the control population’s private health care usage and travel costs. Resource use and unit cost data 
were also included from the local private hospice care unit. 
Medicines. Outpatient medicine costs related to PC were extracted from SII’s electronic records and 
compared to those of the control population. The cost of medication for the treatment of PC 




The work status of the patients and the potential retirement from work due to PC were obtained 
from the patient survey. Patients were asked whether they were working, retired due to cancer, 
retired due to other reasons or not working due to some other reason. The registries of SII were used 
to calculate the number of days patients were on sick leave and absent from work due to PC during 
the six-month observation period. 
The human capital approach (HCA) was used to value loss of productivity (Hanly et al 2012). To assess 
the loss of productivity, gross wages (pre-tax) were translated into average labour costs by including 
employer’s social security payments in addition to pre-tax salary (Hujanen et al 2008). Actual annual 
gross wages (pre-tax) were used when calculating productivity losses due to early retirement. The 
valuation of productivity losses due to sick leave followed the same approach, however, average 
daily cost of labour was based on actual wages.  
 
Informal care 
Using a background questionnaire, the patients estimated the number of weekly hours of informal 
care received. Informal care was defined as care that patients had received free of charge from 
family members and friends. These estimates were used to extrapolate the costs to the six-month 
observation period in each disease state. 
There is no established approach for calculating the value of informal care, and the proxy good 
method was chosen in which the value of informal care is calculated by multiplying the number of 
hours of informal care by the value per hour for each care task performed. In the proxy good method 
the value per hour is based on the shadow price of a market substitute. This provides valuable insight 
into the costs of replacing informal care with formal care (Hoefman et al 2013). To value informal 
care, a practice nurse’s mean hourly pre-tax salary was used and translated into the hourly labour 
cost by adding side costs on top of pre-tax salary. 
 
 Statistical methods 4.5
 
In general, key demographic characteristics were reported as proportions and HRQoL utility scores in 
different states of PC as unadjusted means, standard deviations, and 95% confidence intervals. The 
mean EQ-5D-3L and 15D scores and the 15D profile for each disease state were compared with those 
of the general population using the Student’s independent samples t-test. For comparison, the 
samples of the general population were weighted to reflect the age, gender, and education 
distribution of the patient samples. The determinants of HRQoL (scores from EQ-5D-3L, 15D and VAS) 
were analysed using the ordinary least square (OLS) regression model. Separate models for localised 
and metastatic PC were built in a stepwise (backward) regression, in which the choice of predictive 
variables is carried out by an automatic procedure using the significant p-value of 0.10 for removal of 
variables. Clinical and demographic factors and EORTC symptoms served in the models as 




Costs were reported as the mean costs in different states of PC. The statistical significance of the 
differences in costs and resource use between the disease states was tested by using confidence 
intervals (95%). Fixed log linear multivariate models were built to analyse how background factors 
are associated with total costs. Total costs were used as the dependent variable and, due to skewed 
distribution of cost variables, natural logarithm transformation was applied. Age, cohabiting, 
educational level, and symptoms and functioning scales (physical, role, social, emotional and 
cognitive functions) measured with the EORTC QLQ-C30 were used as independent variables. Three 
different models were built: one for primary treatment, one combining remission and rehabilitation, 
and one for metastatic disease. A risk level of 5% was used for type 1 error in all analyses.  
 
The distributions of the utility scores for each instrument are shown visually. Deviations of the utility 
score distributions from normal distribution were tested by using the Kolmogorov-Smirnov test and 
differences between the mean scores by paired samples t-tests. Skewness and kurtosis of the 
distributions are also reported. HRQoL instruments internal consistency was analysed with 
Cronbach’s alpha.  
 
The linear associations between the scores of the instruments (EQ-5D-3L and 15D) were analysed by 
using interclass correlation coefficient (ICC) and Pearson correlation. The ICC was performed by a 
two-way mixed model with absolute agreement definition and average measure. Bland and Altman 
plot was used to show the mean difference between paired 15D and EQ-5D-3L scores (mean 
difference line) and associated 95% limits of agreement (upper and lower limits), for the combined 
data sample.  
 
All statistical analyses were performed using Statistical Package for the Social Sciences (SPSS) (IBM 








 Patients (I-III) 5.1
 
A total of 1025 PC patients were approached, of whom 630 (61.5%) responded. Their ages ranged 
from 44 to 93 years (mean 69). Most of the participating patients had local disease and were married 
or cohabiting and had higher education. The mean time from diagnosis was 3.0 years and within the 
last 3 months, 19% of the patients had received luteinizing hormone releasing hormone (LHRH) 
analogue treatment, which was a commonly used option in metastatic disease. Almost half of the 
Metastatic patients had chemotherapy and a similar share in the Palliative group received 
radiotherapy. The patient characteristics by disease states are shown in table 3. 
Table 3. Patient characteristics by disease states. 
  Primary Rehabilitation Remission Metastatic Palliative All patients 
Respondents (%) 47 158 317 89 19 630 
Demographic factors             
     Age, mean (SD) 68.5 (8.2) 68.3 (8.2) 69.1 (7.8) 71.4 (7.9) 75.5 (8.3) 69.4 (8.1) 
     Higher education, %  28 (59.6) 52 (32.9) 173 (54.6) 48 (53.9) 7 (36.8) 279 (55.4) 
     Married/cohabiting, (%)  38 (80.9) 80 (50.6) 256 (80.8) 69 (77.5) 14 (73.7) 457 (82.0) 
Disease-related factors 
           Time after diagnosis, years (SD) 0.14 (0.5) 1.2 (0.1) 3.4 (1.0) 5.4 (4.4) 8.1 (4.5) 3.0 (2.6) 
     Time after metastases, years 
(SD) - - - 2.2 (2.2) 2.6 (2.0) 2.3 (2.2) 
     Bone metastasis (%) - - - 81 (91.0) 18 (94.7) 99 (15.7) 
Treatments, within last 3 months           
Radiotherapy, (%)  0 (0.0) 3 (1.9) 2 (0.6) 10 (11.2) 8 (42.1) 23 (3.7) 
Antiandrogene therapy, (%) 0 (0.0) 7 (4.4) 16 (5.0) 19 (21.3) 3 (15.5) 45 (7.1) 
Zoledronic acid, (%) 0 (0.0) 0 (0.0) 0 (0.0) 17 (19.1) 2 (10.5) 19 (3.0) 
LHRH-analogue, (%) 1 (2.1) 25 (15.8) 25 (7.9) 64 (71.9) 5 (26.3) 120 (19.0) 
Chemotherapy, (%)  0 (0.0) 0 (0.0) 3 (0.9) 36 (40.4) 3 (15.8) 42 (6.7) 
  
Unfortunately it was not possible to analyse the non-respondents. Access to patient records was not 
permitted when a patient did not want to participate and did not give an informed consent. The only 
analysis that was possible concerned patients’ age. There was no difference between respondents 
and non-respondents regarding age (69.4 years vs 68.2 years, respectively).  
 
 Use of single index HRQoL instruments in PC (IV) 5.2
 
The literature search identified a total of 2,010 references of which 237 studies were obtained for 
full-text assessment. After the review of the full-text articles, 33 studies were judged to fulfil the 
inclusion criteria and were thus included in the qualitative synthesis of the systematic review.  
Of the 33 articles, 24 (73%) utilized an indirect valuation and 16 (48%) a direct valuation method 
(some of the studies included both approaches). The most commonly used instrument was the EQ-
5D-3L, which was used in 21 (64%) studies. The Visual Analogue Scale (VAS) was also common as it 
was used in ten (30%) studies. TTO was used in six (18%) studies which all originated from the USA. 
(Table 4).  
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Table 4. Summary of characteristics of publications included. 










Early/localised     
Knight et al 2004, USA Newly diagnosed localised PC 95 TTO 0, 3, 12 
Elstein et al 2005, USA Localised PC 127 TTO 0, 3-6 months 
later 
Korfage et al 2005, Netherlands Localised PC 314 EQ-5D, VAS -1, 6, 12, 52  
Sommers et al 2008, USA  Localised PC 167 TTO 0 
Soyupek et al 2008, Turkey  Locally advanced PC 20 15D 0 
Fernández-Arjona et al 2012, Spain Locally advanced or disseminated PC 561 EQ-5D, VAS 0 
Advanced/metastatic     
Saad et al 2002, multinational  Hormone-refractory metastatic  PC 
patients 
643 EQ-5D 0, 15  
Reed et al 2004, USA  Advanced PC (treatment of SRE) 1469 EQ-5D 0, every 3 months 
Weinfurt et al 2005, multinational  Metastatic PC with sign of SRE 248 EQ-5D, VAS 0, 3 month up to 
24 months 
Sullivan et al 2007, multinational  Metastatic hormone-refractory PC 
patients 
280 EQ-5D 0, 3, 6, 9  
Namiki et al 2008, Japan Advanced or metastatic PC 23 EQ-5D 0, 3, 6, 9 and 12  
Wu et al 2008, USA  Metastatic hormone refractory PC 280 EQ-5D 0, 3, 6, 9  
Färkkilä et al 2013, Finland  Palliative PC, BC, CRC 30 15D, EQ-5D, VAS 0 
Skaltsa et al 2014, multinational  Metastatic castration-resistant PC 209 EQ-5D 0, 13 and every 
subsequent 12 
week 
Diels et al 2015, multinational  Metastatic castration-resistant PC 602 EQ-5D 0 
Loriot et al 2015, multinational  Asymptomatic and minimally 
symptomatic, chemotherapy-naive 
patients with metastatic castration-
resistant PC 
1717 EQ-5D 0, weeks 5, 13, 25, 
37, 49, 61 
Saad et al 2002, multinational  Hormone-refractory metastatic  PC 
patients 
643 EQ-5D 0, 15 
Screening     
Booth et al  2012, Finland  PC screening 5516 15D, EQ-5D, SF-
6D 
surveys in 1998, 
2000, 2004, 2011 
Prostatectomy     
Smith et al 2002, USA  After radical prostatectomy 209 TTO, SG 0 
Glazener et al 2011, UK  Radical prostatectomy or TURP 853 EQ-5D 3, 6, 9, 12 
Wang & Eriksson 2014, Sweden  PC patients at least 10 years after 
laparoscopic radical prostatectomy 
49 EQ-5D 0 
Mixed/other     
Krahn et al 2003, Canada  PC 141 HUI, QWB 0 
Stewart et al 2005, USA  PC, older than 60 162 SG 0 
Volk et al 2004, USA  PC screening and metastatic PC 168 TTO 0 
Krahn et al 2007, Canada  Three cohorts: newly diagnosed, 
metastatic and other 
248 HUI 2/3, EQ-5D, 
QWB 
0, 2, 12 
Pearcy et al 2008, UK, Ireland  PC 25 VAS 0 
Shimizu et al 2008, Japan  Localised PC and hormone refractory 
PC 
323 EQ-5D 0 
Meghani et al 2009, USA  PC or men at risk 188 TTO/VAS single time-point 
Pickard et al 2009, USA  PC 87 EQ-5D, VAS 0 
Cameron et al 2012, Canada  PC patients after radiotherapy 73 EQ-5D, VAS 0, 1 
Ruland et al 2013, Norway  PC and BC patients 325 15D 0, 3, 6, 12 
Mickeviciene et al 2013, Lithuania  PC 501 VAS 0 
Torvinen et al 2013, Finland  PC patients (different states) 630 15D, EQ-5D, VAS 0 
Freytag et al 2014, USA (135) Intermediate-risk PC 44 EQ-5D 0, 6, 12, 24, 36  
EQ-5D-3L; EuroQoL,HUI; Health Utilities Index, QWB; Quality of Well-being, SF-6D; Short Form 6D, AQoL-8D; Assessment of Quality of Life 
TTO; Time-Trade-off, SG; Standard Gamble, VAS; Visual Analogue Scale, PC; Prostate Cancer, BC; Breast Cancer, CRC; Colorectal Cancer 
*Months if not mentioned otherwise in the text. 
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Based on the literature review, in localised and early stage disease, the HRQoL scores varied from 
0.63 to 0.91. The impact of radical prostatectomy on HRQoL was studied in five of the articles, and 
the HRQoL scores after surgery varied between 0.68 and 0.91. In advanced or metastatic stage 
disease the HRQoL scores varied according to the literature review between 0.50 and 0.87. The 
variation in HRQoL scores between the various disease stages is most probably a consequence of 
variation in the HRQoL instruments used and variation in the study methods. These HRQoL scores 
can be seen only as indicative and cannot be directly compared due to different characteristics of the 
instruments (e.g., scales, etc.). 
 
 HRQoL in different states of PC (I) 5.3
 
The 15D scores of the study population ranged from 0.344 to 1.000 (mean 0.868). Altogether 30 
patients (5%) were in full health (i.e., their 15D score was 1). The EQ-5D scores of the study 
population ranged from -0.166 to 1.00 (mean 0.845). With the EQ-5D, a ceiling effect was evident: 
266 patients (42%) were in full health. The VAS score ranged from 1 to 100, with a mean of 76.4 
(Table 5). 30 patients reported having full health with VAS (VAS=100). The mean scores of all 
instruments were consistently lower in the more advanced disease states. Instruments internal 
consistency was also analysed. Cronbach alpha for the 15D was 0.87, EQ-5D: 0.793, and EORTC 0.863. 
These results are suggesting that the instruments and their items have relatively high internal 
consistency. Reliability coefficient of 0.70 or higher can be considered “acceptable” in most social 




Table 5. Mean HRQoL scores in different disease states. 
  EQ-5D-3L 15D VAS 
  Mean N SD 95% CI Mean n SD 95% CI Mean n SD 95% CI 
Primary  0.900 46 0.19 0.84-0.96 0.914 47 0.09 0.89-0.94 81.11 46 14.87 76.69-85.52 
Rehabilitation 0.887 91 0.14 0.86-0.92 0.888 157 0.09 0.87-0.90 76.73 92 16.69 73.27-80.18 
Remission 0.866 309 0.19 0.85-0.89 0.880 310 0.11 0.87-0.89 79.80 311 16.24 77.99-81.62 
Metastatic 0.742 85 0.27 0.69-0.80 0.805 88 0.12 0.78-0.83 66.79 86 21.80 62.12-71.46 
Palliative 0.590 17 0.22 0.48-0.70 0.671 19 0.10 0.62-0.72 48.67 18 19.10 39.17-58.17 
All patients 0.845 548 0.21 0.83-0.86 0.868 621 0.11 0.89-0.94 76.36 553 18.56 74.81-77.91 
  
 
However, as long as the disease was local, the mean HRQoL scores remained close to the baseline 
level; significantly impaired mean HRQoL scores were seen only after the disease had progressed to 
the metastatic stage. Both generic instruments gave higher scores in the Primary and Rehabilitation 
groups than those of the age- and gender-standardised general population (EQ-5D also in the 
Remission state) (Table 5). In the Metastatic state the mean EQ-5D and 15D scores were both 
clinically and statistically significantly lower than in the Remission state, and in the Palliative state, 
lower than in the Metastatic state. Lowest mean values were thus seen in the Palliative care state. Of 
the 15D dimensions, only sleeping, excretion, and sexual activity were statistically significantly worse 
in the Rehabilitation group than in the age- and gender-standardised general population. In the 
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Primary group, patients fared better than did the general population on the dimensions of speech, 
mental function, and discomfort and symptoms, and in the Rehabilitation group on the dimensions of 
mobility, vision, usual activities, mental function, discomfort and symptoms (Table 6). 
 
Comparison against the age- and gender-standardised general population is important as it can 
illustrate incremental health issues in this relatively aged group. Therefore, it was somewhat 
surprising that in general, HRQoL was at a high level. In localised disease, PC patients’ HRQoL was 
numerically higher or at the same level compared to general population peers with both generic 
instruments (EQ-5D-3L and 15D), however, when looking from a MID perspective the differences 
were not clinically important. When the disease progressed to metastatic state, HRQoL decreased 
both statistically significantly and clinically importantly.  
 
Table 6. The mean deviations of PC patients’ HRQoL scores measured by the 15D and EQ-
5D-3L from those of the age- and gender-standardised general population. 
 
Primary ∆ Rehabilitation ∆ Remission ∆ Metastatic ∆ Palliative ∆ 
EQ-5D-3L 0.116 ***  0.060 ***  0.050 ***  -0.053 *  -0.153 **  
15D index 0.025   0.012   -0.001   -0.068 *** -0.177 *** 
15D dimensions           
Mobility 0.019  0.033 *** 0.012  -0.066 ** -0.260 *** 
Vision 0.008  0.036 *** 0.005  -0.003  -0.102 * 
Hearing  -0.013  0.018  0.005  -0.026  -0.183 ** 
Breathing 0.017  0.037  0.012  -0.054 * -0.104  
Sleeping 0.012  -0.009 ** -0.026 * -0.058 * -0.121 * 
Eating -0.005  0.009  0.003  0.003  -0.032  
Speech 0.022 *** 0.017  0.012  0.019 * -0.056  
Excretion -0.010  -0.044 ** -0.043 *** -0.134 *** -0.293 *** 
Usual activities 0.029  0.047 *** 0.015  -0.106 *** -0.272 *** 
Mental function 0.081 *** 0.048 *** 0.037 *** 0.021  -0.045  
Discomfort and symptoms 0.082 *** 0.065 *** 0.046 *** -0.080 *** -0.180 *** 
Depression 0.032  0.016  0.009  -0.026  -0.137 *** 
Distress  0.003  0.001  -0.010  -0.029  -0.165 *** 
Vitality 0.036  0.010  -0.003  -0.110 *** -0.255 *** 
Sexual activity -0.042   -0.229 *** -0.205 *** -0.446 *** -0.544 *** 
∆, difference compared to the general population (positive for better scores compared to general population). 
* = p-value < 0.05; ** = p-value < 0.01; *** = p-value < 0.005. 
  
Graphically the 15D profiles can be produced in different ways and formats. Two different ways of 
illustrating the same thing are shown in Figure 5. The profiles show on what dimensions, and how 
severe problems (the smaller the level value, the more severe problems) the different groups of 
patients have. The profiles and changes in profiles are reflected in the 15D scores adjacent to the 
profiles.  
 
The 15D profile highlighted the difference between local and metastatic disease in terms of 
decrements on different dimensions of HRQoL (Figure 5). In local disease, dimension values are close 
to each other with the exception of sexual activity where already Rehabilitation and Remission 
groups were worse off than the Primary group. In the Palliative group the values are the lowest, and 
patients report a lot of problems on the dimensions of mobility, excretion, usual activities, 
















































































































































The EORTC QLQ-C30 showed that the patients with metastatic disease exhibited more symptoms 
than did patients with local disease; the Palliative group was the most symptomatic (Figure 6). 
Reported symptoms followed the progression of the disease stages. Only pain, diarrhoea and 
financial difficulties were reported more often in the Primary group than in the Rehabilitation group, 
and constipation occurred in the Rehabilitation group more often than in the Remission group. The 
mean EORTC QLQ-C30 Global Health score was 75 (range: Primary 81 to Palliative 49). The EORTC 
yielded different functioning scores in different disease states in line with those of the two other 
HRQoL instruments studied here (Figure 7). 
 
Figure 6. EORTC QLQ-C30 functionality scales in different states of PC. 
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EORTC QLQ-C30 symptoms scale 0-100; 0 = no patients have reported; 100 = all patients are reporting 
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 HRQoL in palliative care (II) 5.4
 
Even with increased attention to cancer patients’ HRQoL in general, so far the understanding of 
terminal stages of cancer is still limited. In this study the patient selection was based on two criteria: 
patients with metastatic disease and receiving palliative treatments only (defined by no 
chemotherapy or radiotherapy), and patients who died due to cancer within 6 months of responding 
to the questionnaire, irrespective of the treatment given. Their treatment followed routine clinical 
guidelines and was in no way affected by the study.  
Within all three cancers (PC, CRC, BC) 311 palliative cancer patients were invited to participate, 115 
(37%) responded. In addition, in the hospital palliative care unit and in the hospice, questionnaires 
were given to patients who were willing and capable of participating. The 15D scores were calculated 
for 114 patients (24% had BC, 26% had PC, and 50% had CRC), and EQ-5D and VAS scores for 111. All 
EORTC QLQ-C30 functioning and symptom scales were calculated for 101 patients. 
Mean utility scores varied widely depending on the instrument used: the 15D gave the highest utility 
values and the VAS gave the lowest. The mean utility value within the study population (i.e., average 
within CRC, BC and PC) measured by the 15D was 0.74, and when measured by the EQ-5D-3L and the 
VAS, it was 0.59 and 55, respectively. The mean utility value among PC patients was 0.67 with the 
15D, 0.59 with the EQ-5D-3L, and 48.7 with the VAS. All generic instruments we used were applicable 
for the measurement of HRQoL in end-stage cancer, however, across all patients (all 3 cancers) 13% 
of patients reported being in perfect health, i.e., a HRQoL score equal to 1 with the EQ-5D-3L, which 
raises questions on the usability of the EQ-5D-3L with end of life situations. 
Of the EORTC QLQ-C30 functioning scales, physical, role, and social functionality were the most 
impaired among all patients. With patients closer to death, physical and role functioning deteriorated 
the most, while other functioning scales remained mainly unaffected. Fatigue was the most 
prominent symptom in each cancer group, followed by pain, and constipation (in case of PC). PC 
patients reported symptoms between BC (which had most symptoms) and CRC (lowest frequency of 
symptoms) patients. PC patients also reported less financial difficulties and diarrhoea compared with 
BC and CRC patients. With patients closer to death, fatigue, nausea and vomiting, pain, dyspnoea, 
appetite loss, and constipation were more common. Fatigue was reported by almost every patient 
(98%), and 82% of patients reported having at least some pain, 64% of the patients answered that 
they had at least some depression. 
 
 Factors associated with HRQoL (I) 5.5
 
The analysis based on a multivariate regression model for localised PC showed that fatigue, pain and 
financial difficulties were significant factors associated with HRQoL assessed with all instruments, and 
dyspnoea, insomnia, and age, when assessed with 15D and VAS. In a multivariate model using only 
the metastatic patient population (advanced disease model) fatigue and pain associated negatively 
with HRQoL scores assessed with all instruments. Further analysis focusing on background variables 
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revealed (EORTC symptoms were excluded) that not having higher education, high age and financial 
difficulties were the most important factors associated with decreased HRQoL scores. In advanced 
disease, financial difficulties and age proved to be the most significant variables.  
One of the key findings was that, beyond the rather obvious factors such as symptoms and age, 
financial difficulties seem to be an important factor related to the poor HRQoL of PC patients. 
Table 7. Factors associated with HRQoL in PC. 
 EQ-5D 15D VAS 
 Std coefficient P-value Std coefficient P-value Std coefficient P-value 
Localised disease R2 = 0.564 R2 = 0.738 R2 = 0.471 
Fatigue -0.003 *** -0.002 *** -0.318 *** 
Dyspnoea   -0.001 *** -0.098 *** 
Pain -0.003 *** -0.001 *** -0.102 *** 
Insomnia   -0.001 *** -0.078 *** 
Age -0.002 *** -0.002 ***   
Financial difficulties -0.001 *** -0.001 *** -0.117 *** 
Diarrhoea   -0.001 ***   
Watchful waiting   -0.023 *** -3.903 * 
Cohabiting 0.037 *     
Higher education 0.028 *   2.530 * 
Appetite loss -0.002 ***     
Anti-androgen treatment     -8.439 *** 
Time after diagnosis/recurrence     0.940 * 
Constipation   -0.001 ***   
Nausea vomiting   -0.001 *   
Metastatic disease R2 = 0.714 R2 = 0.712 R2 = 0.492 
Age   -0.002 * -0.002 * 
Fatigue -0.005 *** -0.003 *** -0.320 *** 
Financial difficulties -0.002 **     
Watchful waiting**** 0.145 ***     
Dyspnoea   -0.001 ***   
Pain -0.003 *** -0.001 *** -0.300 *** 
Anti-androgen treatment -0.082 *     
 *=p-value<0.05; **=p-value<0.01; ***=p-value<0.005; ****Watchful waiting is defined as patients who do not receive any cancer 
treatments/operations.  
 
 Costs in different states of PC (III) 5.6
 
Costs reported in this study can be used in various types of analyses as they are reported as 
incremental costs due to cancer for a six-month period and they include direct medical costs, 
productivity costs and costs of informal care.  
 
Direct health care costs 
The mean total direct costs increased substantially after detection of metastases and differed 
markedly from the costs related to localised disease states. The costs were highest in the metastatic 
state of the disease (Table 8). The mean primary health care costs were relatively modest, being 
twice as high in newly diagnosed patients compared to the other states. Private health care costs 
were fairly similar to those observed in the control group. In localised disease, a small additional cost 
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from the use of private health care was observed. However, in the metastatic state of the disease 
patients used less private health care than their control group. The mean costs of medicines were 
lowest in recently diagnosed patients, while the mean travel costs were highest in the Metastatic 
state. 
 
Table 8. Direct healthcare costs by disease state in PC (€). 
Cost item Primary Rehabilitation Remission Metastatic 
Specialist Care  2,162 539 251 2,661 
(95% CI) (1,418 ─ 2,906) (345 ‒ 734) (165 ‒ 336) (2,105 ‒ 3,217) 
Primary Health Care 421 195 200 175 
(95% CI) (-80 ‒ 921) (55 ‒ 355) (104 ‒ 295) (115 ‒ 234) 
Private Health Care 36 42 18 -29 
(95% CI) (-21 ‒ 93) (-17 ‒ 102) (-18 ‒ 55) (-54 ‒ -5) 
Medication 141 307 304 4,354 
(95% CI) (-5 ‒ 287) (76 ‒ 537) (99 ‒ 509) (3,481‒5,228) 
Travelling -10 59 -12 263 
(95% CI) (-66 ‒ 46) (-21 ‒139) (-29 ‒ 4) (117 ‒ 409) 
Total Healthcare costs  2,750 1,143 760 7,423 
(95% CI) (1,853 ‒ 3,647) (777 ‒ 1,508) (479 ‒ 1,041) (6,199 ‒ 8,647) 
Negative value means less resource usage compared to non-PC control group (private health care and travelling costs). 
All costs are for 6-month period. 
 
Productivity costs 
Most of the patients were not working which was expected considering their advanced mean age. Of 
the patients, 102 (16.7%) were employed and of the 430 retired patients more than two thirds were 
eligible for the state pension based on their age of 65 or more. Only 18 patients (2.9%) were 
receiving disability pension due to their cancer, and 28 patients (4.6%) were receiving disability 
pension due to reasons other than cancer. Seventeen patients (2.8%) reported being unemployed or 
not working. 
 
The number of days absent from work due to sick leave was relatively low, being on average less 
than one day during the six-month period. However, in the metastatic group it was almost four days. 
The mean number of days patients were absent from work due to early retirement was much higher, 
being highest in the Metastatic and Primary treatment groups (8.6 and 7.7 days, respectively) (Table 
9). 
 
The estimated productivity losses were highest in the Primary and Metastatic groups (Table 9). Most 
of the productivity losses came from early retirement and the impact of sick leave was limited, being 












Table 9. Productivity losses in PC. 
 Days absent from work due to 
sick leave (95% CI) 
Days absent from work due to early 
retirement (95% CI) 
Total days absent from 
work due to PC 
Primary 0.5 (0.47 – 1.29) 7.7 (-3.16 – 18.65) 8.20 
Rehabilitation 0.8 (0.78 – 1.76) 4.6 (0.10 – 9.11) 5.40 
Remission   4.0 (1.06 –7.00) 4.00 
Metastatic 3.9 (3.89 – 8.06) 8.6 (0.20 – 16.93) 12.50 
 Productivity loss due to sick 
leave (95% CI), € 
Productivity loss due to early 
retirement (95% CI), € 
Total value of productivity 
loss, € 
Primary 107 (101 – 276) 1,759 (-722 – 4,260) 1,866 
Rehabilitation 171 (167 – 377) 727 (16 – 1,440) 898 
Remission   786 (208 – 1,375) 786 
Metastatic 834 (832 – 1,725) 3,443 (80 – 6,779) 4,278 
 
Informal care 
Only 34 patients (5.6%) received informal care due to PC either from their family or others. The mean 
number of hours of informal care in localised disease was modest (around one hour per week or 
less), but increased with disease progression, being highest in the Metastatic group (6.5 hours per 
week). The estimated value of informal care during the six-month period was highest in the patient 
group with advanced disease (Table 10). 
 
Table 10. Cost of informal care in PC. 
 
N 
Mean number of 
hours of informal care 
per week 
Cost of informal care 
(6 months), € (95% CI), € 
Primary 47 1.2 589 (-506 – 1,684) 
Rehabilitation 158 0.5 242 (-68 – 553) 
Remission 317 1.1 540 (-217 – 1,299) 
Metastatic 89 6.5 3,180 (110 – 6,250) 
 
Multivariate regression analysis revealed that patient characteristics and background factors 
explained 9-27% of the variance in total costs associated with PC in various states of the disease 
(Table 11). From background factors, higher education seemed to lead to higher costs in newly 
diagnosed patients and cohabiting was associated with a lower cost burden in the Metastatic state. 
When analysing QLQ-C30 symptoms scales, emotional functioning in the Primary state was 
statistically significantly positively associated with costs, whereas physical functioning in the 
Remission/Rehabilitation state was significantly negatively associated with costs. Regarding QLQ-C30 
functionality scales, costs were statistically significantly higher when patients reported more 









Table 11. The results of multivariate analyses of cost drivers with the natural logarithm of 
total costs as the dependent variable (PC).  
  Primary treatments 
  Remission/   
Metastatic    Rehabilitation     
Variable   Coefficient P-value   Coefficient P-value   Coefficient P-value 
  
R2  = 0.273   R2  = 0.151   R2  = 0.089 
 (Constant) 9.050  8.555  9.737  
Characteristics          
     Age, years -0.130 0.551  -0.089 0.071  -0.071 0.586       Cohabiting 0.155 0.305  -0.047 0.307  -0.308 0.015 *      Higher education 0.443 0.012 * -0.019 0.686  0.058 0.645  
QLQ-C30 Symptom scales        
     Global health 0.326 0.225  -0.030 0.645  -0.129 0.473       Physical functioning 0.021 0.951  -0.210 0.003 * -0.105 0.640       Role functioning -0.431 0.136  -0.014 0.851  0.073 0.770       Emotional functioning 0.469 0.012 * 0.117 0.074  0.123 0.566       Cognitive functioning -0.406 0.115  -0.013 0.831  0.147 0.424       Social functioning -0.183 0.256  -0.019 0.747  -0.253 0.158  
QLQ-C30 Functionality scales  
     Fatigue -0.041 0.882  -0.016 0.801  -0.103 0.562  
     Nausea/vomiting -0.113 0.547  0.274 0.000 * -0.045 0.750  
     Pain 0.448 0.062  -0.055 0.302  0.139 0.381       Dyspnoea 0.095 0.685  -0.032 0.534  0.214 0.164       Insomnia -0.239 0.372  0.026 0.622  -0.089 0.484       Appetite loss -0.043 0.848  0.067 0.199  0.173 0.270       Constipation -0.072 0.650  -0.027 0.558  0.195 0.145       Diarrhoea -0.056 0.698  0.040 0.373  0.168 0.199       Financial difficulties 0.227 0.209   0.107 0.034 * -0.041 0.748   
 
*=p-value<0.05 
       
         The share of productivity costs out of total costs (combined direct health care costs and productivity 
costs) varied between 37% and 51% in different states of the disease. However, when informal care 
costs were also included, the share of indirect costs (productivity costs and informal care costs) 
increased to 47─64% out of total costs (combination of direct health care costs, productivity costs 
and informal costs).  
 
Based on the results, direct costs for a six-month period in localised PC, especially in the early 
treatment phase, may not be as high as in the case of some other cancers (e.g., CRC etc.)(Färkkilä et 
al 2015). Also, the estimates for a six-month period in the subsequent states (Rehabilitation and 
Remission) show that resource use is moderate and the costs of interventions or adjuvant 
medications used in PC are relatively modest. The costs, however, started to accumulate when the 
disease progresses. 
 
Productivity loss due to sick leave was modest, however, more losses being generated by early 
retirement. Overall, only 177 patients (29%) were younger than 65 years, and consequently still 
below the general retirement age, and only 17% of the total number of patients were working, 
curtailing the potential productivity losses. 
 
Direct costs related to different states of PC are significant and productivity losses and costs of 
informal care play a major role when estimating the total burden of PC. Excluding such a large share 
56 
 
of costs from cost effectiveness considerations might have a significant impact on the decision 
making process of health economic evaluations or health technology assessments (HTA). 
 
 Characteristics and interchangeability of the EQ-5D and 15D (I) 5.7
 
One aim of this thesis was to describe differences between two generic HRQoL instruments (EQ-5D-
3L and 15D) in PC, and to evaluate whether they can be used interchangeably. The mean utility 
scores were close to each other (EQ-5D-3L: 0.845; 15D: 0.868), and they correlated fairly well 
(Pearson correlation r = 0.714). The distribution of the scores differed from normal although the 
distribution of the 15D scores was closer to normal than that of the EQ-5D-3L scores. There was a 
moderate agreement between the scores (Interclass correlation coefficient (ICC) = 0.752). Internal 
consistencies were analysed for HRQoL instruments and Cronbach alphas were for the 15D: 0.870, 
EQ-5D: 0.793, and EORTC QLQ-C30: 0.863. These results are suggesting that the instruments and 
their items have relatively high internal consistency. Nevertheless, the study results suggest that the 
two studied instruments cannot to be used interchangeably, or at least such an approach needs to be 
taken cautiously.  
 
Discrimination 
In localised disease (higher HRQoL) there were only small differences in the mean scores between 
the instruments, but after the disease progresses to a metastatic stage (lower HRQoL) more 
differences can be found (e.g., Table 5). For example, among patients who received palliative care, 
the EQ-5D-3L produced a much lower mean score (0.590) compared to the 15D (0.671). This was 
seen already in the metastatic state, where the mean 15D score started to decrease from that 
observed in localised disease. These results suggest that differences between instruments in the 
mean scores, especially in the lower end of the utility range, are both statistically significant (paired 
t-test) and clinically important.  
 
The proportion of high HRQoL scores (EQ-5D/15D ≥ 0.75) was higher with the 15D than with the EQ-
5D. However, HRQoL scores above 0.5 were almost as prevalent with the 15D (99%) as with the EQ-
5D-3L (96%).  
 
Table 12. Comparison of utility values in PC (mean).  
HRQoL instrument EQ-5D-3L 15D 
% share of the utility values in the following subgroups 
≥0.75 72.4% 85.0% 
0.5-0.74 23.5% 14.0% 
0.25-0.49 1.1% 1.0% 
0-0.24 1.8% - 




Plotted distributions of the 15D and the EQ-5D-3L scores in PC are shown in Figures 8 and 9. The 
Kolmogorov-Smirnov test was used to confirm that both distributions differed from a normal 
distribution, but the 15D distribution clearly less. Both distributions were negatively skewed (15D -
1.118, EQ-5D-3L -2.134) indicating long left-hand tails which are also visually apparent. Kurtosis (15D 
1.141, EQ-5D-3L 6.361) suggested that the relatively large standard deviation of the EQ-5D-3L can 
result from infrequent extreme deviations.  
 
Figure 8. Distribution of the HRQoL scores 
with 15D in PC.  
 
Figure 9. Distribution of the HRQoL scores 
with EQ-5D-3L in PC.
   
 
Agreement of HRQoL scores between the EQ-5D and the 15D  
The distribution of the HRQoL scores produced using the EQ-5D-3L was discontinuous, had a long tail 
with low HRQoL scores and a peak with the highest possible HRQoL score. The long tail is partly 
explained by health states with negative EQ-5D-3L scores. The share of negative HRQoL scores was 
1.1% using the EQ-5D-3L. The distribution for the 15D was continuous, slightly skewed to the right 
and very low HRQoL scores were missing (only 1% between 0.25 and 0.49). The Bland–Altman 
graphical method verified the differences between the instruments. The dissimilarities between the 

















Figure 10. Bland-Altman plot. 
 
Figure 10. Bland and Altman plot showing the mean difference between paired 15D and EQ-5D scores (mean difference line) and 
associated 95% limits of agreement (upper and lower limits), for the combined data sample. The markers represent the difference between 




The association between the EQ-5D-3L and the 15D scores was relatively good (ICC = 0.75). The linear 
correlation (Pearson) between the two was 0.714. In the lower end of the utility range the linear 
correlation decreased. All these correlations were statistically significant (p<0.01).  
 
The ceiling effect (the percentage of patients in full health, i.e., score = 1) was prominent with the 
EQ-5D-3L: 266 patients (42%) obtained the score of full health (=1), whereas with the 15D this was 
5%. A floor effect was not seen, although 6 (1%) patients obtained an EQ-5D-3L score < 0 (0 = being 




upper limit = 0.309 
mean difference = 0.020 





This study revealed that the use of generic HRQoL instruments in PC research has been limited. HTA 
bodies and European authorities are increasingly demanding evidence on cost-effectiveness, and 
CUA has gained ground as the method of choice when assessments are performed. For CUA, QALYs 
are needed, and sometimes HTA bodies may require that they are based on assessments performed 
by certain pre-defined instrument (e.g., EQ-5D-3L for NICE). Based on the literature review, such data 
may be limited, and the use of mapping algorithms may be more frequent in the future. 
PC patients’ HRQoL remained at a relatively high level as long as the patients’ disease remained 
localised. The 15D produced higher scores compared to the EQ-5D-3L in general. In localised disease 
HRQoL was at a similar level as that of the age- and gender-standardised general population. One 
explanation for this finding could be that a significant proportion of patients enter PC treatment 
because of elevated prostate-specific antigen (PSA) levels found in opportunistic testing, and have 
minor or no symptoms at all that would impair HRQoL. As PSA testing has not been recommended at 
the national level, such an opportunistic testing in Finland is currently limited mainly to occupational 
health services. Based on the Finnish national health survey, localised PC patients also valued their 
HRQoL higher than did patients with other types of cancer (Saarni et al 2006). This study provides 
detailed information on PC patients’ HRQoL with different instruments in different states of disease, 
and this data can be used also outside Finland in health economic analyses.  
 
In Finland the cost burden of PC has been mainly evaluated in the context of other cancers and this 
study complement that research. Stage specific HRQoL data or incremental costs compared to age-
standardised peers have not been presented before in Finland. Some earlier estimates on cost 
burden have been presented and based on that it seems that PC generates a major share of the 
cancer cost burden for the society (Mäklin & Rissanen 2006; Syöpätautien asiantuntijaryhmä 2014). 
This is expected as PC is one of the most prevalent cancers. The total healthcare costs per patient 
were relatively modest in the Rehabilitation and Remission groups, but naturally higher in groups 
where more active treatment interventions take place (i.e., after diagnosis and when the disease 
becomes metastatic). The cost results of this study are presented as incremental costs due to PC 
compared to age, gender and place of residence standardised general population peers and are in 
agreement with some previous estimates (Luengo-Fernandez et al 2013; Mehra et al 2013). 
 
The literature review on single index HRQoL instruments 
The literature search identified over 2000 studies on HRQoL of PC patients, but only 33 of them were 
eligible for the final systematic review. The most commonly used instrument in those studies was the 
EQ-5D-3L, which was used in 21 studies. Based on the literature, in localised PC disease-specific 
domains like urinary, sexual and bowel function are the most profoundly affected domains, whereas, 
with some exceptions, general HRQoL usually remains mostly unaffected (Eton & Lepore 2002; 
Torvinen et al 2013). The substantial disutility of asymptomatic disease observed in one study was 
thought to reflect more the anxiety caused by the uncertainty of not knowing whether the cancer 
would spread than the current actual state of health (Steward et al 2005). Krahn et al (2003) 
concluded that although sexual, urinary and bowel dysfunction are common in PC, their impact on 
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overall health status may have been overestimated if utility scores have been derived from 
hypothetical scenarios or from individuals without the disease. For localised and early stage disease, 
the HRQoL scores reported in the literature were relatively well in agreement with the 15D and EQ-
5D-3L results observed for localised disease in this study. The sexual activity dimension was naturally 
affected in the 15D as low values were reported already when the disease was local, but especially 
after detection of metastases. Longitudinal follow-up studies on HRQoL are needed to draw more 
accurate conclusions on the HRQoL impact of the side effects of the treatments in localised and early 
PC (Korfage et al 2005). 
In the advanced or metastatic PC, many of the reviewed articles focused on the HRQoL effects of 
skeletal-related events (SREs) and found a significant impact of SREs on HRQoL (Reed et al 2005; 
Weinfurt et al 2005; Sullivan et al 2007), although in the study by Saad et al (2002), the observed 
deterioration of HRQoL in patients with SREs was not statistically significant. One might argue that 
this may be due to the insensitivity of the generic EQ-5D-3L instrument that was used, but Weinfurt 
et al (2005), and Sullivan et al (2007), found a significant HRQoL impact related to SREs using the 
same instrument. Pain is a frequent symptom associated with SREs, and many HRQoL studies 
therefore incorporate also disease-specific instruments, such as the Brief Pain Inventory (BPI) or the 
EORTC QLQ-C30, which include a pain domain. In this study over 20% of the patients reported pain in 
the Metastatic, and roughly half in the Palliative group (EORTC QLQ-C30).  
Costs 
The total costs varied quite substantially between the disease states. Results support previous 
findings that PC is an expensive cancer to treat, especially in the advanced state (Kalseth et al 2011). 
Total direct health care costs for a six-month period varied between €760 and €7,423 depending on 
the state of the disease. Direct costs in localised PC, especially in the early treatment phase, 
however, may not be as high as in the case in some other cancers (i.e., CRC, etc.)(Färkkilä et al 2015).  
 
Productivity losses varied between disease states, and were fairly low in localised disease but 
naturally increased in advanced disease states. The share of productivity losses out of all costs was 
prominent (47-64%). There is uncertainty over how to assess productivity losses, and according to 
Hanly et al (2012), results may differ substantially between approaches. However, so far there is no 
consensus on this topic and the human capital approach was chosen as being the most commonly 
used. It has been estimated that indirect costs may result in up to 70% of the total burden of disease 
in breast cancer patients (Lidgren et al 2007). These results can be considered to be on the same 
level compared to the indirect (productivity) costs observed in this study. 
 
The costs of informal care have been less studied than direct costs or productivity losses, but they 
may add significantly to the total cost burden of the disease. On average, the total number of hours 
of informal care received was very modest, which, however, was not true for those 34 (6%) patients, 
who actually received such care and used it intensively. Most of these patients had more advanced 
disease. As clinical information was not collected, it is not possible to evaluate why these patients 
needed this amount of informal care or whether other patients received some other type of support 
that this study was not able to capture. Nevertheless, informal care plays an important part in the 
support network of PC patients and more research is needed to reveal its true role. A recent study 
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HRQoL results  
The EORTC QLQ-C30 showed that the patients with metastatic disease exhibited more symptoms 
than did patients with local disease. Reported symptoms followed the progression of the disease 
stages. Only pain, diarrhoea and financial difficulties were reported more often in the Primary group 
than in the Rehabilitation group, and constipation occurred in the Rehabilitation group more often 
than in the Remission group. Fatigue was reported by around one fifth of the patients with local 
disease, but by approximately 40% after metastasis. Nausea and vomiting were relatively infrequent 
in all patient groups and less than 10% reported it in metastatic disease state, in which around half of 
the patients were receiving chemotherapy. It seems that anti-nausea medications are used 
effectively and patients are able to undergo treatments as planned. Around 20% of the patients were 
reporting insomnia.  
 
The generic instruments, EQ-5D-3L and 15D, produced results which are in-line with the results of 
previous studies included in the literature review. In local disease, HRQoL is at a relatively high level 
and comparable to that of age-matched peers. In advanced disease, the mean HRQoL scores were 
clinically importantly and statistically significantly lower than in patients with localised disease. The 
variation in HRQoL scores between the various disease states is most probably partly also explained 
by the different HRQoL instruments used. The HRQoL deterioration was most pronounced in patients 
in whom the disease had progressed to the palliative care state. In palliative care, PC patients’ HRQoL 
was lower compared to that observed in CRC patients, but at the same level as in BC patients. One 
reason for this could be bone metastases, which are more common in BC and PC compared to CRC. 
This finding was supported by lower functionality scales and more symptoms in PC and BC patients. 
In general, there was no data available from these instruments in the palliative patient group. End-of-
life patients were able to answer the study questionnaire (altogether 76 questions) and the answers 
were consistent with all instruments, which can be interpreted that all instruments are applicable to 
this patient group. However, a high ceiling effect for the EQ-5D-3L is something that questions the 
validity of the EQ-5D-3L in the HRQoL measurement of end-of-life patients’. 
 
This study aimed at generating HRQoL data in different states of the disease and therefore analysis of 
the impact of different treatment options (surgery, radiation etc.) on the HRQoL was out of scope of 
the study. Further research is needed to provide more information on this topic as it could inform 
patients and physicians on the potential consequences of the different treatment choices. These 
study results serve better health economic analysis than individual treatment choices but reveal 
some general information regarding HRQoL in different states of the disease (e.g., symptoms that 




Interchangeability of the EQ-5D-3L and 15D 
European authorities, individual countries and local agencies are currently not in the same phase 
regarding the use of health economic/health technology assessments. There are efforts towards 
European-wide assessments (e.g., EMA, EUnetHTA), local agencies are implementing cost-
effectiveness assessments, and for instance NICE in the United Kingdom, is moving to value-based 
assessment. This is interesting, as NICE has recommended that burden of illness (BOI) should be used 
to weight QALY gain in future value-based assessment (Rowen et al 2016b). At the same time, for 
instance Spain has followed a different path and walked away from using QALYs in HTAs, like 
Germany and the US did already earlier. 
 
This study corroborated earlier findings that there are considerable differences in the results 
produced by the HRQoL instruments - one of the most evident was the ceiling effect: 42% of the 
patients were in full health according to the EQ-5D-3L, but only 5% according to the 15D. Even within 
palliative patients, the ceiling effect with the EQ-5D-3L was prominent, 13%. In the light of such 
findings, the validity of EQ-5D-3L is questionable for these patient groups. In general, these findings 
are in-line with previous studies and result from the different features of the instruments, mainly 
different descriptive systems (questionnaires) and ranges of health state values and the shape of the 
distribution of scores (Conner-Spady & Suarez-Almazor 2003; Brazier et al 2004; Marra et al 2004; 
Tsuchiya et al 2006; Lillegraven et al 2010; Vainiola et al 2010). In comparison between EQ-5D-3L and 
15D, the mean utility scores were close to each other, and correlated fairly well. The distribution of 
the scores differed from normal although the distribution of the 15D scores was closer to normal 
distribution than that of the EQ-5D-3L scores. There was moderate agreement between the scores. 
As measured by the number of health states defined by the instrument, the health state descriptive 
system of the 15D is much richer, especially in comparison with the EQ-5D-3L. The valuation space of 
the EQ-5D-3L (-0.59–1.00) is about 60% longer than that (0–1) of the 15D.  
 
Based on the results, the EQ-5D-3L and the 15D should not be considered interchangeable in health 
economic evaluations, especially in cases where HRQoL values are low, or differ significantly from 
those of age-standardised peers. The marked ceiling effect, discontinuous distribution of EQ-5D-3L 
scores divided into two main groups, as well as the higher HRQoL scores obtained by the 15D 
compared to EQ-5D-3L, and no scores between 0.88 and 1.00 for the EQ-5D-3L (a joint effect of the 
health state descriptive system and valuation system), are findings that have been earlier reported 
also in other diseases (Saarni et al 2006; Vainiola et al 2010; Heiskanen et al 2016). These differences 
need to be taken into consideration when these instruments and their results are used in health 
economic evaluations. However, further research should be performed as this study is lacking 
information on HRQoL instruments responsiveness over time. Nevertheless, in daily clinical practice, 
the proportion of patients reaching the positive MID (EQ-5D-3L: 0.08, 15D: 0.015) could be a more 
patient-centric outcome for monitoring clinical success than the cumulative numbers of QALYs 
gained (Heiskanen et al 2016).  
 
Factors associated with HRQoL 
For the analysis of factors affecting HRQoL across different disease states and different instruments, 
two linear ordinary least squares (OLS) regression models were developed: one for local disease and 
the other for metastatic disease. The analyses revealed that beyond symptoms, financial difficulties 
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and age were the most important explanatory factors impairing HRQoL in both regression models. 
These results are in line with those of earlier published studies (Jayadevappa et al 2005; Song et al 
2011). Treatment options failed to explain the variance in patients’ HRQoL values. The OLS regression 
approach may have its limitations as the distributions of the scores produced by the generic 
instruments analysed here, especially the EQ-5D-3L, failed to satisfy the distributional assumptions 
required by traditional OLS. Although, based on the literature, the choice of using a more complex 
regression method has rather little significance for the 15D, this may not hold true for the EQ-5D-3L 
(Saarni et al 2006). 
One of the key findings was that beyond the rather obvious factors such as symptoms and age, 
financial difficulties seem to be an important determinant related to the poor HRQoL of PC patients. 
In palliative care symptoms, especially fatigue, will lead to impairment of both activities of daily living 
and psychological functioning, and therefore fatigue seems to be the most significant factor 
deteriorating HRQoL, whereas clinical and demographic factors had less effect on HRQoL. 
Furthermore, patients’ functionality, as measured by the EORTC QLQ-C30, was also impaired, 
especially in the physical, role, and social dimensions. This was also evident when the study results 
were compared with the general population reference values available from Germany and Sweden 
(Michelson et al 2000; Schwarz & Hinz 2002). 
 
Strengths and limitations of the study 
The most important limitation of the study is the cross-sectional study design. It might have been 
more effective to follow the same patients throughout their disease progression. However, this 
would have needed a much longer follow-up time. As this was a cross-sectional study, it was not 
possible to analyse HRQoL instruments responsiveness to change. The response rate was 61.5%, 
which can also be seen as a limitation. Analysis of the ages revealed that there were no differences 
between responders and non-responders but unfortunately it was not possible to do further analysis 
without consent to participate to study. Although there are no reasons to believe that absence of 
non-responders would have impacted the study results. 
 
One potential limitation could also be the use of the UK TTO tariff for EQ-5D-3L, especially in terms of 
comparing results with the 15D in a Finnish setting. However, there is no local TTO tariff available 
and also most previous EQ-5D-3L studies in Finland have used the UK TTO tariff. Currently there is 
also a five level (five answer options per question) version (EQ-5D-5L) available (Herdman et al 2011), 
however, the country-specific value sets are lacking and therefore the use of this newer version is 
limited at the moment. For instance NICE has expressed in 2017 that they will continue for the time 
being to recommend the 3-level as the basis for submissions (EuroQol 2017). 
A key strength on this study is the holistic approach; having two generic HRQoL instruments (15D and 
EQ-5D-3L) and a disease-specific instrument (EORTC QLQ-C30). They allow different types of 
analyses, and also a comparison of results obtained with different instruments. Our analysis of cost 
data can be judged to be robust and includes direct costs, productivity costs and cost of informal 
care. What makes this unique is the use of a control group that allow to focus on costs that are 





The fact that the patients were not categorised inside the five disease states according to treatments 
they had received and the analyses included all the patients representing the real-life situation in PC 
care, can also been seen as a strength of the study. Most other analyses are limited to study certain 
interventions and patients are included or excluded according to the intervention that is under 
evaluation. Although this gives a robust estimate of the efficacy of the intervention, it does not 
reflect the everyday situation in health care units, where different types of PC patients are treated 
with multiple interventions.  
 
Transferability of the results outside Finland depends on the need of the data. Cost data are typically 
reflecting efficiency of the health care system and should be used with caution outside the system 
where they have been collected. HRQoL data are something that is currently often used across 
borders. There the key for using these data is to standardise treatments and/or disease states to be 
able to reliably estimate that the target patient population is similar to the source population.  
 
In general, the internal consistency of the HRQoL questionnaires was at a good level as measured by 
Cronbach’s alpha. All these questionnaires have been are validated earlier and these results can be 
used to depict the HRQoL of these patient groups with robust external validity. Differences and the 
agreement between instruments were analysed in different ways (e.g., ICC and Bland–Altman plot). 
In general, there were no major reasons to question the internal validity, i.e., credibility, of the 
findings obtained with these instruments. An exception is the high ceiling effects with the EQ-5D-3L 
in seriously ill patient groups, where one would not expect a high number of scores indicating full 
health. 
 
Cost data from hospital registries and other registries can be divided into two parts: volumes (e.g., 
number of treatments) and unit cost. First ones are reliable and bias could come from miscoding, 
while latter ones can be challenged to be as good as methods that were used to estimate or calculate 
those unit costs (e.g., how well are the hospitals able to calculate resources used for producing 
different services or procedures).  In general there are no reasons to believe that there would be any 
systematic bias or that prices would not be based on the best estimate on the production cost 
behind them. For example public hospitals are owned by the municipalities and prices should reflect 
the production cost of these services. Similarly prices of the drugs are true prices that are paid by the 
society. When estimating the amount of productivity losses incurred or informal care obtained, it is 
not so easy to verify what is the most apropriate method to estimate them. Nevertheless, labor cost 
was based on real wages (pre-tax gross) and employer’s social security payments and this method is 
be as realistic as possible, but of course there are some limitations when using the human capital 
approach. Calculations of productivity losses caused by early retirement and sick leaves followed 
more or less the same approach. Similarly, the number of hours of informal care obtained was based 
on a questionnaire which could be challenged as patients were asked to report the amount of 
services used during the last three months. In terms of cost data, the external validity i.e., 
transferability and generalizability can be challenged unless the environment can be controlled or 
matched with the source situation. 
The study results give important baseline information regarding costs and HRQoL in different states 
of disease. The results can be compared, combined or used as an alternative/supportive data set in 
any health economic / cost analysis dealing within PC. If combined with national epidemiological 
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data, these data could be used even e.g., when analyzing potential cost-effectiveness of screening of 









7. CONCLUSIONS AND IMPLICATIONS 
 
• HRQoL assessments in PC, especially in the context of preference-based single index 
measures that can be used directly for QALY estimations, are scarce. Given the fact that PC is 
one of the most common cancers, it is important to focus on the treatment options and on 
their unique effects on the quantity and quality of life, while not forgetting the evaluation of 
the cost-effectiveness of these options. 
• All evaluated HRQoL instruments in this study provided valuable insight into patients’ overall 
HRQoL. Symptoms of fatigue and pain, and background variables of financial difficulties and 
age were the most important factors associated with poor HRQoL.  
• Direct costs related to different states of PC are significant. However, productivity losses and 
costs of informal care also play a major role when estimating the total burden of PC. 
Excluding such a large share of costs from cost effectiveness considerations might have a 
significant impact on the decision making process of health economic evaluations or HTA. 
• Additional studies are still needed to better appreciate the impact of the increasing 
economic burden of PC management. The aging of the population will substantially increase 
the demand for all health care resources, and PC is definitely one of the areas where a 
significant number of patients will be diagnosed and treated. Also the rational use of 
screening should be kept in evaluations. From a health policy perspective, more research is 
needed to make appropriate choices on allocation decisions to guarantee the rational use of 
health care resources. 
• In the end-of-life care, some differences between cancer types were found: CRC patients 
reported slightly higher mean utility scores than BC and PC patients. Several reasons could 
account for this: symptom burden was lowest in CRC patients, bone metastases known to be 
painful were less frequent, and the time from primary diagnosis and first metastasis was 
shorter than in BC and PC patients. In comparison, BC patients were the most symptomatic 
and had the most impaired HRQoL, which might, at least partly, be explained by the longer 
duration of the sickness in BC, younger age, and the predisposition to bone metastases. 
• Generic HRQoL instruments (EQ-5D-3L and the 15D) should not be considered 
interchangeable in health economic evaluations, especially in the case where HRQoL values 
are low or differ significantly from those of age-standardised peers. For instance in end-of-
life care, the EQ-5D resulted in a 13% ceiling effect. The EQ-5D-3L produces greater 
differences in utilities than the 15D. The marked ceiling effect and the two-peaked, 
discontinuous distribution of the EQ-5D-3L scores, as well as the higher HRQoL scores 
obtained by the 15D compared to EQ-5D-3L, have been earlier reported in other diseases. 
Thus, these differences need to be taken into consideration when these instruments and 
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tapahtuvaan  tietojen  keräämiseen  ja niiden  käsittelyyn. Voin myöhemmin peruuttaa  suostumukseni 
sen vaikuttamatta mitenkään saamaani hoitoon.  
Annan  tällä  suostumuksella  luvan  siihen,  että  oheisilla  kyselylomakkeilla  kerätyt  tiedot  saadaan 
yhdistää  muihin  minua  koskeviin  Helsingin  ja  Uudenmaan  sairaanhoitopiirissä  oleviin  hoitotietoihin 
sekä Tilastokeskuksen, Terveyden  ja hyvinvoinnin  laitoksen (THL)  ja Kansaneläkelaitoksen (KELA) sekä 
kotikuntani  sairauteni hoitoa koskeviin  tietoihin. Ymmärrän, että henkilötunnuksella varustettu  tieto 
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HEL S I N GI N  J A  U UD E N M A A N  S A I RA A NH O IT
 
   














matkalaukun kantaminen teistä työläältä?  1  2  3  4 
2. Tuntuvatko pitkät kävelymatkat työläiltä? 1 2  3  4
3. Tuntuvatko lyhyet kävelymatkat kotinne ulkopuolella 
työläiltä?  1  2  3  4 
4. Pitääkö teidän pysytellä levolla tai istumassa päivän 
mittaan?  1  2  3  4 
5. Tarvitsetteko apua ruokaillessanne, pukeutuessanne, 









päivittäisistä toimistanne?  1  2  3  4 
7. Oliko teillä rajoituksia harrastus‐ tai muissa vapaa‐ajan 
toiminnoissanne?  1  2  3  4 
8. Oliko teillä hengenahdistusta?  1 2  3  4
9. Oliko kipuja?  1 2  3  4
10. Tunsitteko levontarvetta?  1 2  3  4
11. Oliko unettomuutta?  1 2  3  4
12. Tunsitteko heikotusta?  1 2  3  4
13. Oliko ruokahaluttomuutta?  1 2  3  4
14. Oliko pahoinvointia?  1 2  3  4














16. Oliko ummetusta?   1 2  3  4
17. Oliko ripulia?  1 2  3  4
18. Olitteko väsynyt?  1 2  3  4
19. Häiritsikö kipu päivittäisiä toimianne?  1 2  3  4
20. Oliko teillä keskittymisvaikeuksia esim. sanomalehteä 
lukiessanne tai televisiota katsellessanne?  1  2  3  4 
21. Olitteko jännittynyt?  1 2  3  4
22. Olitteko huolestunut?  1 2  3  4
23. Olitteko ärtynyt?  1 2  3  4
24. Olitteko masentunut?  1 2  3  4
25. Oliko teidän vaikea muistaa asioita?  1 2  3  4
26. Häiritsikö hoito tai fyysinen kuntonne perhe‐elämäänne? 1 2  3  4
27. Häiritsikö hoito tai fyysinen kuntonne sosiaalista 
kanssakäymistä?  1  2  3  4 
28. Aiheuttaako fyysinen kuntonne tai hoito taloudellisia 


























 Minulla on jonkin verran vaikeuksia kävelemisessä       
 Olen vuoteenomana       
Itsestään huolehtiminen 
 Minulla ei ole vaikeuksia huolehtia itsestäni       
 Minulla on jonkin verran vaikeuksia peseytyä tai pukeutua itse      




 En kykene suorittamaan tavanomaisia toimintojani        
Kivut/vaivat 
 Minulla ei ole kipuja tai vaivoja      
 Minulla on kohtalaisia kipuja tai vaivoja       
 Minulla on ankaria kipuja tai vaivoja       
Ahdistuneisuus/Masennus 
 En ole ahdistunut tai masentunut       
 Olen melko ahdistunut tai masentunut 
















terveydentila  on,  olemme  piirtäneet  lämpömittaria 
















ja  tehkää  tämä  vetämällä  alla olevasta  laatikosta  viiva  siihen 
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14. Erilliskäynti laboratoriossa tai 
röntgentutkimuksissa 
____ kertaa viimeisen 3 kk aikana 
15. Kuinka monta kertaa olette viimeisen kolmen 
kuukauden aikana ollut sairautenne vuoksi 
yhteydessä puhelimitse sairaanhoitajaan tai 
lääkäriin?  
____ kertaa viimeisen 3 kk aikana 
16. Kuinka monta kertaa olette viimeisen kolmen 
kuukauden aikana tavannut kotonanne 
sairautenne vuoksi kotisairaanhoitajan tai 
terveydenhoitajan?  
____ kertaa viimeisen 3 kk aikana 
17. Kuinka monta kertaa viimeisen kolmen 
kuukauden aikana luonanne kotona on käynyt 
teitä hoitamassa/auttamassa kodinhoitaja tai 
kotiavustaja sairautenne vuoksi?  
____ kertaa viimeisen 3 kk aikana  
18. Miten paljon olette saanut hoitoa ja apua 
perheeltänne tai ystäviltänne sairautenne 
vuoksi keskimäärin viikossa viimeisen kolmen 
kuukauden aikana?  
Keskimäärin ____ tuntia/viikossa viimeisen 3 kk 
aikana 
Kuinka monta kertaa ja vuorokautta (vrk) olette 
ollut viimeisen kolmen kuukauden aikana hoidossa 
seuraavissa paikoissa? 
19. Terveyskeskuksen vuodeosastolla  
____ kertaa yhteensä ____ vrk viimeisen  
3 kk aikana 
20. Keskus‐ tai yliopistosairaalassa 
____ kertaa yhteensä ____ vrk viimeisen  
3 kk aikana 
21. Muussa yleissairaalassa (aluesairaalassa) 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
22. Yksityisessä sairaalassa 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
23. Kuntoutuslaitoksessa 
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
24. Kunnallis‐/vanhainkodissa,  
____ kertaa yhteensä ____ vrk  
viimeisen 3 kk aikana 
LÄÄKEMENOT 
25. Arvio, kuinka paljon olette käyttäneet rahaa 
lääkkeisiin viimeisen kolmen kuukauden (3 kk) 
aikana?  
______ € viimeisen 3 kk aikana 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Kiitos vaivannäöstänne. 
